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Fetal medicine is a relatively young and fast growing field of medicine. The first 
successful fetal treatment was the intrauterine blood transfusion for Rhesus hemolytic 
disease in 1963 (by Dr. A.W. Liley). Since then, both the number of indications as the 
number of fetal treatment options have expanded rapidly. With the introduction of 
ultrasound, prenatal diagnosis of a wide range of fetal diseases became possible. In 
addition, ultrasound guided techniques enabled the development of minimally invasive 
prenatal treatments. Therefore, ultrasound and fetal medicine are inextricably linked. 
Sonographic observations provided a growing insight in the physiology and the 
pathophysiology of human fetuses. However, as a young and developing field of 
medicine, many questions still have to be answered at a fundamental level.  
Physiology is the basis for our understanding of both health and disease state. 
Research in this area in human adults has resulted in the development of many 
diagnostic tools, medicines and other treatment modalities. Furthermore, experimental 
animal studies have provided many answers on questions that were impossible to 
investigate in humans. However, distinct differences can make it difficult to translate 
findings from animal experimental models to the human situation. Especially the 
human placenta is a unique organ, not comparable to that of any other mammal. 
Further, lessons can be learned from studies in premature neonates of the same 
gestational age as a fetus. However, radical changes take place after birth, especially 
in the cardiovascular system, making direct comparisons often impossible. 
As a tertiary fetal therapy center, the LUMC has an obligation, besides high quality 
patient care and performance of clinical trials, to develop scientific projects on basic 
research level. A unique possibility is provided to study human fetal (patho-) physiology, 
by the access to the fetal circulation and amniotic fluid during treatment of several 
fetal diseases. Both the etiology of prenatal diseases and the reaction of fetuses on 
prenatal treatment can be investigated. Potentially treatable fetal diseases include 
fetal anemia, twin related problems, primary cardiac failure, primary hydrothorax and 
other causes of non-immune hydrops fetalis. All of these diseases can lead to 
abnormal amniotic fluid volumes, i.e. oligo- or polyhydramnios, which can result in a 
premature delivery of a neonate in a critical condition. Moreover, all of these diseases 
inevitably lead to the development of hydrops fetalis, eventually leading to intra 




The development of abnormal amniotic fluid volumes and hydrops fetalis form the 
final common pathway of all these fetal diseases and are in fact shifts in fluid and 
protein in the different fetal compartments. These shifts take place between the 
amniotic fluid and the intravascular and the interstitial compartment in both the fetus 
and the placenta. The mechanisms involved in these fetal fluid and protein dynamics 
will be investigated in the studies described in this thesis. With increasing insight in 
the pathophysiological processes, improvements can be made in the diagnosis of 
disease stages, in timing of fetal treatment, in new treatment modalities and even 
in preventive strategies for these high risk prenatal conditions. 
From clinical practice, several questions arose. First of all, diagnosis of fetal anemia 
and the timing of intrauterine blood transfusion has been a subject of interest at our 
department since several decades. One of the oldest diagnostic tools, measuring 
bilirubin content in amniotic fluid, developed by Bevis in 1956 [1] and introduced into 
clinical practice by Liley in 1961 [2], has been a clinically useful tool for many years. 
Surprisingly, detailed studies on the background of this test are lacking. Secondly, 
treatment of fetuses with intrauterine blood transfusion still carries a substantial risk 
of complications or fetal loss. Treatment methods were developed empirically, and 
are practically unchanged since the late 1980s. More basic knowledge on fetal 
condition during developing anemia and on fetal reaction to blood transfusion could 
potentially lead to adaptation and refinement of management protocols, with increased 
safety of this procedure. 
Finally, the studies described in this thesis are aimed to bring forth an increased 
understanding of fetal physiology in general. This can contribute to the development 
of fetal therapy for a wider range of obstetric complications as oligo- and 





The studies in this thesis were performed in fetuses with hemolytic alloimmune 
anemia. Yearly, around 90 intrauterine blood transfusions are performed in the LUMC 
to treat this disease.  
Fetal hemolytic alloimmune anemia
Hemolytic alloimmune anemia used to be the main cause of hydrops fetalis [3] and 
one of the most important causes of perinatal death before 1960 [4]. It was commonly 
referred to as erythroblastosis fetalis. In red cell alloimmunization a woman’s immune 
system is sensitized to foreign red blood cell surface antigens, stimulating the 
production of IgG antibodies. The most common routes of maternal sensitization are 
via blood transfusion or after feto-maternal hemorrhage. Feto-maternal hemorrhage 
can occur for example during spontaneous or induced abortion, ectopic pregnancy, 
trauma, invasive obstetric procedures, and delivery, espacialy traumatic parturition, 
with consequences for a subsequent pregnancy. The antibodies can cross the placenta 
and, if the fetus is positive for the red blood cell surface antigens, lead to hemolysis of 
fetal red blood cells and fetal anemia. Of the more than 50 different antigens causing 
hemolytic disease in the fetus and newborn, the D antigen of the Rhesus blood group 
system (Rh D) causes the most cases of prenatal severe hemolytic disease in the fetus 
and newborn  [5;6]. With the introduction of intrauterine blood transfusion, the possibility 
of prenatal detection of anemia, improved neonatal care and last but not least the 
preventive administration of anti-D immunoglobulins, an enormous decrease has taken 
place of alloimmune anemia and immune hydrops fetalis, in the last 40 years [7;8]. 
Diagnosis of fetal hemolytic anemia
The diagnosis of fetal hemolytic anemia can be established by fetal blood sampling. 
However, the invasive nature of this procedure introduces a risk to the pregnancy 
and to further boostering of alloimmunization. Signs of fetal anemia can be observed 
with ultrasound i.e. cardiomegaly, hepato- and splenomegaly and signs of hydrops. 
Furthermore, fetal anemia can be predicted by Doppler blood flow measurements 
or by amniotic fluid analysis.  Both of these diagnostic tools are quite accurate in 
prediction of fetal anemia [9;10], however, the measurement of the peak systolic 
velocity in the middle cerebral artery can predict severe anemia with higher accuracy 
than bilirubin determinination in amniotic fluid [9]. Moreover, the great advantage of 
sonographic measurements is the fact that it is not harmfull for the pregnancy. 
However, below 18 weeks and above 36 weeks of gestation, the measurement of 
the peak systolic velocity in the middle cerebral artery appears less accurate or more 
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difficult to obtain. Also, maternal obesity, abnormal position of the fetus or concomitant 
pathology can make prediction of fetal anemia with ultrasound difficult. Then 
measurement of bilirubin content (usually delta OD450 measurement) by 
amniocentesis may help the clinician in timing of the more invasive cordocentesis 
and a first transfusion. The so-called Liley or Queenan charts show the cut-off values 
for bilirubin content in amniotic fluid that indicate the risk of fetal anemia. The 
diagnosis of fetal anemia is finally confirmed by the sampling of fetal blood.  
Intrauterine transfusion
Intrauterine transfusion is an ultrasound guided procedure. Puncture of the umbilical 
vein is performed either at the cord insertion, through the anterior placenta, or in the 
intra-abdominal hepatic portion of the umbilical vein. Fetal blood is sampled for 
analysis and an intravascular blood transfusion can be performed. Another option is 
an intraperitoneal transfusion of donor blood. Red cells will then be absorbed from 
the peritoneal cavity, through lymphatic drainage, towards the intravascular 
compartment. Although this method was replaced by the intravascular method in 
the 1980s, renewed interest has brought it back to use recently, often in combination 
with intravascular transfusion to prolong the transfusion-interval. At the LUMC, 
intrauterine transfusions are performed as early as 16 weeks of gestation and repeat 
transfusions are given every 2-5 weeks up to 35 weeks [11]. After birth, aimed 
between 36 and 38 weeks of gestation, phototherapy, transfusions and/or exchange 
transfusions may be necessary to treat recurrent anemia and hyperbilirubinemia. The 
procedure related risk of fetal loss is 1.6% for every intrauterine transfusion [12]. 
Risk factors are low gestational age and severe hydrops. Improvement of the most 
commonly used fetal therapy is therefore still an important subject of investigation.
Hydrops fetalis
Hydrops fetalis is the condition where a fetus retains an abundant amount of fluid. 
It is defined as the presence of an abnormal fluid collection in two or more fetal 
compartments. It can be recognized on ultrasound as fetal ascites, pericardial effusion, 
hydrothorax, (generalized) subcutaneous tissue edema, placental edema or 
polyhydramnios. Hydrops fetalis can be classified as immune or non-immune hydrops, 
based on whether or not alloimmunization underlies the etiology. This classification 
was traditionally used, since non-immune hydrops usually was not treatable and 
implied a poor prognosis. Recently, classification as anemic or non-anemic hydrops 
has been proposed [13]. Nowadays, this is a useful classification, since many hydropic 
fetuses can benefit from an intrauterine blood transfusion. Besides alloimmune 




hemorrhage. Other groups of causes can be identified that can benefit from fetal 
therapy [14]. One of these groups are twin related problems, such as twin reversed 
arterial perfusion sequence or twin-to-twin transfusion syndrome, that can be treated 
with laser ablation of intertwin connecting blood vessels. Other causes include 
primary hydrothorax that can benefit from thoraco-amniotic shunt placement or fetal 
arrhythmia that can benefit from transplacental drug treatment. Chromosomal, 
genetic, or metabolic disorders or congenital infections as CMV should be excluded 
since these are generally non-curable causes of hydrops fetalis. 
The similarity between both anemic and non-anemic hydrops fetalis is the occurrence 
of cardiovascular changes, either as a primary or a secondary effect. Understanding 
of the cardiovascular pathophysiology in fetal hemolytic anemia and immune hydrops 
can therefore be helpful in the understanding of many other fetal diseases and might 
improve different types of fetal therapy. 
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Outline of the thesis
The studies described in this thesis explore fetal pathophysiology in hemolytic 
anemia and immune hydrops fetalis. Measurements performed in fetal blood as 
well as in amniotic fluid, before or during intrauterine transfusion, where used for 
our research. 
The studies in this thesis can be summarized as follows:
The mechanism behind the curve of the so-called Liley chart has never been fully 
understood. In chapter two, we investigated the relation between bilirubin 
concentration in fetal blood and that in amniotic fluid. We hypothesized on the most 
plausible pathway for bilirubin to enter and leave the amniotic fluid.
In chapter three, we tested the hypothesis that the concentration of bilirubin is 
determined by the binding to albumin. Thereby we tried to explain the relation 
between fetal anemia and the Liley chart. This led to the next question: how does 
albumin enter and leave the amniotic fluid?
In chapter four, we reviewed the available evidence on the origin of albumin in 
amniotic fluid and the transport mechanisms that determine amniotic fluid composition. 
We speculate on the function of albumin in amniotic fluid and propose directions for 
future research and development of new fetal therapy strategies. 
In chapter five, we investigated whether low albumin concentration was a causative 
or secondary effect in the development of hydrops fetalis. Concentration of albumin 
in fetal blood was analyzed to assess the relation with severity of anemia and severity 
of hydrops.
Fetal cardiovascular physiology may be distinct from adults and even from neonates. 
In chapter six, the maintenance of blood volume was investigated. The effect of 
severity of anemia and the presence of hydrops on total fetoplacental blood volume 
were analyzed. 
In chapter seven, we investigated the extravascular fluid shift that takes place from 
the fetal circulation during intrauterine transfusion. The effect of volume and speed 




Purpose of this thesis was to gain insight in human fetal (patho-)physiology. 
In chapter eight, old, current en acquired knowledge of fetal fluid and protein 
dynamics is described. Furthermore, implications for current practice that followed 
from our studies are discussed and implications for future research are proposed. 
Finally, chapter nine summarizes the results of the presented studies.
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We studied the relationship between bilirubin concentrations in amniotic fluid and 
fetal blood in 68 non-hydropic Rhesus D-alloimmunized anemic fetuses at first blood 
sampling. In these alloimmunized fetuses, the amniotic fluid/fetal blood ratio for 
bilirubin decreased from 0.09 at 28 weeks to 0.05 at 33 weeks. In normal fetuses, 
amniotic fluid/fetal blood ratios for bilirubin, and for albumin, are in the same range 
and show a similar decrease during gestation. We conclude that amniotic fluid bilirubin 
concentration is determined, firstly, by fetal blood bilirubin concentration and, 
secondly, by the amniotic fluid/fetal blood ratio of albumin. Among five possible 
pathways bilirubin could take to build up a concentration in amniotic fluid (fetal 
kidneys, lungs, skin, bowel, membranes), the intramembranous pathway is the only 
one that is compatible with the amniotic fluid/fetal blood ratios for bilirubin that we 
found and must therefore be the most important.
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Introduction
Bilirubin is formed during the degradation of haem-containing compounds, mainly 
hemoglobin [1]. Bilirubin concentration is about four times higher in fetal than in 
maternal blood [2,3]. As a result of this concentration gradient, the unconjugated 
(liposoluble) bilirubin diffuses through trophoblastic layers from fetal to maternal 
blood [4]. It is unclear whether active or passive carrier-mediated transport 
mechanisms play an additional role in placental transfer [5]. Glucuronyl transferase 
activity in the fetal liver is minimal, less than 1 per cent of its activity in neonatal 
and later life, and only a minor fraction of fetal bilirubin is conjugated [3,6]. In the 
fetal situation, this low glucuronyl transferase activity is probably beneficial because 
the clearance of conjugated (hydrophilic) bilirubin through the placental barrier is 
very slow [7]. Unconjugated (hydrophobic) bilirubin in fetal and maternal blood is 
linked to albumin almost completely, and only a minute fraction is free [8]. 
Some of the fetal bilirubin is excreted into the amniotic fluid compartment, and less 
than 10 per cent of this amniotic fluid bilirubin is conjugated [9]. Each day, the fetus 
swallows about 75 per cent of the amniotic fluid volume [10]. Amniotic fluid bilirubin 
concentration is an important diagnostic tool in the management of blood group 
alloimmunization [11]. Little is known, however, about how bilirubin reaches the 
amniotic fluid. Theoretically, there are five major possible pathways bilirubin can take 
to leave the fetal circulation and enter the amniotic fluid: via fetal kidneys, lungs, skin, 
bowel, or via placenta and membranes, which is called the intramembranous pathway. 
A first possible pathway would be via the kidneys. Fetal urine is, after all, the major 
constituent of amniotic fluid after 16-weeks’ gestation. A second pathway would be 
via the lungs. Fetal lung fluid contributes to approximately 10 per cent of amniotic 
fluid [10]. Many clinicians and investigators believe that the fetal lung pathway explains 
the clinically useful relation between amniotic fluid bilirubin concentration and the 
degree of fetal anemia [12]. A third possible pathway, excretion of liposoluble 
substances through the fetal skin along a concentration gradient, probably occurs 
early in pregnancy, but is hampered during the second half of human gestation due
to increasing keratinization [13–15]. Passage of meconium is a fourth possible pathway 
for bilirubin to enter the amniotic fluid. Fetuses regularly pass meconium into the 
amniotic fluid and small lumps of meconium have regularly been seen during 
fetoscopy [16]. A fifth possible pathway is the intramembranous pathway [17]. The 
fetal surface of the placenta is well vascularized and probably plays an important role 
in the volume regulation and composition of amniotic fluid [18]. Under normal 
conditions, diffusion of fluid and solutes between amniotic fluid and fetal blood along 
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this pathway is a fairly rapid process, one that has been shown to occur in both 
directions [7,17].
We wanted to study bilirubin concentrations in human amniotic fluid and fetal blood 
in cases with highly increased hemoglobin degradation, in order to gain more insight 
into the enigmatic relation between these concentrations and to possibly draw some 
conclusions regarding the origin of amniotic fluid bilirubin.
Methods
Leiden University Medical Center is the national referral centre for the treatment of 
fetal anemia in the Netherlands. Our methods for diagnosis and treatment of severe 
fetal alloimmune anemia have been described previously [19]. We searched our 
database from January 1988 to October 2000 for contemporaneous amniotic fluid 
and fetal blood samples that were taken from singleton, rhesus D-alloimmunized, 
nonhydropic, and not previously transfused fetuses. Amniotic fluid samples had to 
have been taken less than 4 days before fetal blood sampling. 
Fetal blood samples were sent to our central laboratory for bilirubin and hematological 
measurements. Values were automatically entered into our database and checked 
by a specialized nurse. Amniotic fluid samples (5–10 ml), protected from light during 
transport, were centrifuged at 1000 g for 10 min to remove vernix and erythrocytes. 
The absorption of the supernatant was measured at the wavelengths 365, 450 and 
550 nm with an UltrospecPlus spectrophotometer (Amersham Pharmacia Biotech, 
UK). The bilirubin absorption, expressed as delta OD450, was calculated as the 
difference between the measured absorption at 450 nm and the background 
absorption at 450 nm, derived from the logarithmic function of the absorptions 
between 365 and 550 nm [11]. 
Normal total bilirubin concentrations in fetal blood increase during gestation. We used 
the reference values proposed by Nava et al. [3], which were derived from a large 
number of normal fetuses undergoing percutaneous umbilical blood sampling 
between 18 and 39 weeks [3]. Normal bilirubin concentrations in amniotic fluid 
decrease during gestation. We used the reference values proposed by Nicolaides et 
al. [20]; these were derived from a large number of amniocenteses in normal 
pregnancies, equally distributed between 16 and 37 weeks [20]. A factor of 1.585 
was used to convert all delta OD450 values to bilirubin concentrations (mg/dl) [21,22]. 
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Normal concentrations of albumin in amniotic fluid and fetal blood were based on 
the literature [23,24].
Results
We found 68 contemporaneous amniotic fluid and blood samples from untransfused 
non-hydropic D-alloimmunized fetuses. Mean gestational age was 29 weeks (range 
21–35). Mean fetal hemoglobin concentration was 6.1 g/dl (range 3.1–10.1). Figure 
1 shows the individual hemoglobin concentrations of fetuses in our study plotted 
against their gestational age. Eight fetuses were moderately anemic (hemoglobin 
concentration 2 to 5 SD below the normal mean) and 60 were severely anemic 
(hemoglobin concentration more than 5 SD below the normal mean) at the time of 
first blood sampling. 
Mean total bilirubin concentration in fetal blood was 5.8 mg/dl (range 1.9–11.4). In all 
but three cases, the conjugated bilirubin concentration was less than 10 per cent of 
the total bilirubin concentration. Figure 2 plots the concentrations of total bilirubin in 
fetal blood against gestational age. Values were above normal in all but one fetus. 
Figure 3 shows the amniotic fluid bilirubin concentrations against gestational age. 
Values were above normal in all but three fetuses. In our study, 50 amniotic fluid 
bilirubin values were in Liley’s zone 3, 13 in the upper third of zone 2 and the remaining 
5 in the lower two thirds of zone 2 [11,25]. 
Figure 4 shows the ratios between bilirubin concentrations in amniotic fluid and in 
blood of the fetuses in our study, plotted against their gestational age. Roughly, these 
ratios decreased from around 0.09 at 28 weeks to around 0.05 at 33 weeks. Thus, 
in our alloimmunized fetuses, these ratios were in the same range as bilirubin and 
albumin ratios in non-immunized fetuses [3,20,23,24], and showed a similar pattern 
of decrease as pregnancy progressed. 
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Figure 1  Hemoglobin values of 68 non-hydropic rhesus D-alloimmunized fetuses at first blood sampling, plotted 
against their gestational age. The grey zone between the three upper ascending lines marks the limits of normal 
fetal hemoglobin concentrations (mean +/-2 SD) [37]*. The lower line separates moderate (between -2 and -5 
SD) from severe (less than -5 SD) fetal anemia.
Figure 2  Total bilirubin values in blood of 68 non-hydropic rhesus D-alloimmunized fetuses at first blood sam-
pling, plotted against their gestational age. The grey zone between the three lines marks the limits of normal 
(mean +/-2 SD) total bilirubin concentration in fetal blood [3]*.
25
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Figure 3  Amniotic fluid bilirubin values of 68 non-hydropic rhesus D-alloimmunized fetuses at first blood sam-
pling, plotted against their gestational age. The grey zone between the three lines marks the limits of normal 
(mean +/-2 SD) bilirubin in amniotic fluid [20]*.
Figure 4  Ratio between amniotic fluid and fetal blood concentrations of total bilirubin in 68 non-hydropic rhesus 
D-alloimmunized fetuses at first blood sampling, plotted against their gestational age. The grey line marks the 
ratio between normal bilirubin concentrations in amniotic fluid and fetal blood [3,20]*. The grey open triangles 




We studied bilirubin concentrations in amniotic fluid and blood in 68 alloimmunized 
fetuses and found that bilirubin values in blood were on average three times as high 
as in non-anemic fetuses. All values were, however, well below the threshold 
associated with a kernicterus risk [26]. Amniotic fluid bilirubin values were also 
elevated, and most values were in Liley’s zone 3, which warrants immediate 
treatment. We then calculated ratios of bilirubin in amniotic fluid to that in blood for 
these anemic fetuses and found these ratios to be very similar to ratios in normal 
fetuses. These ratios were also very similar to ratios of albumin in amniotic fluid to 
that in blood in normal fetuses. These ratios decreased with gestational age from 
around 0.09 at 28 weeks to 0.05 at 33 weeks. 
The strength of the present study is that we measured bilirubin in a relatively large 
number of D-alloimmunized anemic fetuses. None of these fetuses were hydropic 
and this may be important because hydrops is associated with an increase in the 
amniotic fluid/fetal blood ratio of albumin: it has been shown that in hydropic fetuses, 
the blood concentration of albumin decreases and the amniotic fluid concentration 
of albumin increases [27,28]. A weakness of our study is that amniotic fluid samples 
were taken up to three days before fetal blood sampling (we called this 
contemporaneous) whereas one would prefer completely simultaneous samples. 
Prehydropic changes in some of our severely anemic fetuses may also have influenced 
our results. Finally, we did not measure bilirubin in non-anemic fetuses, and therefore 
we had to use normal mean values of bilirubin in amniotic fluid and in blood found in 
the literature [3,20]. Still, we think our results suggest rather convincingly that amniotic 
fluid/fetal blood bilirubin ratios in anemic and non-anemic fetuses are very similar. 
Albumin contains one high affinity binding site for bilirubin and one or two secondary 
sites of lower affinity [1]. Unconjugated bilirubin is hydrophobic and in aqueous 
solutions linked to albumin almost completely [1]. Transfer of bilirubin between body 
compartments, however, is due to diffusion of albumin-free unconjugated bilirubin 
[4]. The bilirubin gradient between compartments is a function of the concentration 
of albumin-free bilirubin and thus of the ratio between bilirubin and albumin in both 
compartments [4]. As early as 1970, Cherry et al. proposed a strong experimental 
argument for this theory, measuring delta OD450 before and 12 h after the injection 
of albumin in the amniotic fluid compartment in 3 alloimmunized pregnancies [28]. 
They found a highly significant linear relationship between delta OD450 and albumin 
concentration. In 1967, Cherry and Rosenfield had already suggested that bilirubin/
27
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protein ratios in amniotic fluid could replace plotting delta OD450 in Liley’s curve and 
suggested a bilirubin/protein ratio of 0.55 as the cut-off. In 1974, Bosch et al. found 
that this ‘Cherry-ratio’ led to slightly more accurate predictions than the Liley chart 
[29]. Our study suggests the existence of a fixed amniotic fluid/fetal blood ratio for 
bilirubin. This ratio decreases between 26 and 34 weeks, probably concurrent with 
the decrease of the amniotic fluid/fetal blood ratio for albumin. It is still unclear which 
factors contribute to the albumin concentration in amniotic fluid. In animal experiments, 
it has been shown that amniotic fluid albumin is, to a large extent, of maternal origin 
and that clearance occurs through fetal swallowing and digestion, as well as through 
absorption through fetal membranes [30,31]. It seems clear that the origins and 
pathways of amniotic fluid albumin are distinct from those of bilirubin, but they are, 
at present, even more puzzling.
We conclude that the bilirubin concentration in amniotic fluid reflects the bilirubin 
concentration in fetal blood. This finding provides a logical explanation for the 
longstanding good performance of Liley’s method in the diagnosis of severe fetal 
alloimmune hemolytic anemia. Further, we found that the amniotic fluid/fetal blood 
ratio for bilirubin mimicked that of albumin. Therefore, we suggest that the ratio 
between bilirubin and albumin in amniotic fluid equals the ratio between bilirubin and 
albumin in blood. The existence of a fixed ratio would shed some light on the origin 
of human amniotic fluid bilirubin: of the five possible pathways bilirubin could take, 
only one would agree with such a fixed ratio. To our knowledge, urinary or alveolar 
fluid concentrations of bilirubin have not been measured in the human fetus. It is 
very improbable, however, that urine or alveolar fluid contribute substantially to the 
bilirubin concentration in amniotic fluid because the protein concentrations in both 
fetal urine and alveolar fluid are 100 to 200 times lower than in fetal plasma [30,32–
34]. The protein concentration in amniotic fluid, on the other hand, is only 10 to 20 
times lower than in fetal plasma [23,24,27,31]. Because of the very low albumin 
concentrations in urine and alveolar fluid, these fluids act as a barrier for unconjugated 
bilirubin leaving the plasma and entering the amniotic fluid compartment. A meconial 
origin of amniotic fluid bilirubin is inconsistent with a clinically relevant correlation 
between amniotic fluid and fetal blood bilirubin concentration. The fetal skin probably 
serves as a major pathway for solute and water exchange between amniotic fluid 
and fetus in early gestation. Fetal skin keratinization begins at approximately 17 weeks 
and a complete stratum corneum is present by approximately 25 weeks [35]. At 14 
to 18 weeks, the skin has been shown to have similar permeability as chorion laeve 
and amnion. However, in fetuses of 24 weeks and older, the skin has become quite 
impermeable [15]. The fetal membranes, on the other hand, retain a high permeability 
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until term [36]. Therefore, bilirubin exchange between fetal blood and amniotic fluid 
most probably occurs through the intramembranous pathway, where both excretion 
and reabsorption of bilirubin take place throughout gestation.
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The study results as presented in chapter 2, are shown here with an addition of 21 
hydropic fetuses. We present 15 mildly hydropic fetuses (semi open dots) and 6 
severely hydropic fetuses (open dots). Fetuses were classified as mildly hydropic in 
case a distinct rim of ascites and/or pericardial effusion is observed. Fetuses were 
classified as severely hydropic in case an abundant amount of fluid collection or skin 
edema is observed. 
In figure 1 it is shown that the bilirubin concentration in fetal blood usually is increased 
in anemic fetuses. However, the severely hydropic fetuses have a relatively low 
concentration of bilirubin in fetal blood, in some cases within or even below the 
normal range. Figure 2 shows the increase in bilirubin concentration in amniotic fluid 
in anemic fetuses. There is no difference observed between nonhydropic and hydropic 
fetuses. Figure 3 shows the ratio of the bilirubin concentration in fetal blood to that 
in amniotic fluid. A large increase is observed in most severely hydropic fetuses, 
compared to non- and mildly hydropic fetuses. 
The low concentration of bilirubin in fetal blood in severely hydropic fetuses could 
be explained either by a diminished hematopoiesis or by a diminished concentration 
and/or binding capacity of albumin in fetal blood. It is intriguing that mildly hydropic 
fetuses seemed not to differ from nonhydropic fetuses, though severely hydropic 
fetuses show distinct differences. 
In conclusion, even though the concentration of bilirubin is relatively low in fetal blood 
in most severely hydropic cases, the bilirubin extinction plotted in Queenan’s or Liley’s 
chart still would predict the presence of severe anemia. A shift in albumin concentration 
(low in fetal blood and high in amniotic fluid) or a change in albumin binding capacity 
could explain the increase in the ratio of bilirubin in fetal blood to that in amniotic 
fluid, in severely hydropic fetuses.
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Figure 1  Bilirubin concentration in fetal blood as a function of gestational age. Normal values are shown [1]*. 
Non-, mildly and severely hydropic fetuses are depicted.
Figure 2  Amniotic fluid ΔOD450 (bilirubin extinction) as a function of gestational age. Cut-off values of the (lin-
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Figure 3  The ratio of the bilirubin concentration in fetal blood to that in amniotic fluid as a function of gestational 
age. The grey line shows the normal ratio* based on reference values of bilirubin in fetal blood [1] and in amniotic 
fluid [2]. Non-, mildly and severely hydropic fetuses are depicted.
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To test the hypothesis that unconjugated bilirubin is equally distributed over the 
albumin molecules present in fetal blood and amniotic fluid in Rhesus (Rh) 
immunization.
Methods
Molar concentrations of unconjugated bilirubin and albumin were measured in fetal 
blood and amniotic fluid samples, obtained before the first intrauterine transfusion 
in 30 nonhydropic, anti-D–alloimmunized fetuses, with gestational ages ranging from 
20 to 35 weeks.
Results
Bilirubin concentration in amniotic fluid was best predicted by a combination of 
bilirubin concentration in fetal blood (p<.001), albumin concentration in fetal blood 
(p=.008), and albumin concentration in amniotic fluid (p<.001) (adjusted R2=0.91). 
The bilirubin/albumin ratios in fetal blood were linearly correlated with the bilirubin/
albumin ratios in amniotic fluid (R2=0.75, p<.001). However, the bilirubin/albumin 
ratios in fetal blood were always higher than the bilirubin/albumin ratios in 
amniotic fluid (regression coefficient 1.4, 95% confidence interval 1.1–1.7). 
In our population, a bilirubin/albumin ratio in amniotic fluid of 0.10 or greater had a 
better sensitivity and specificity to predict severe anemia (Z-hemoglobin –5 standard 
deviations or less) than the Queenan 4 or the Liley 2c line.
Conclusion
The relation between fetal hemolysis and amniotic fluid bilirubin concentration is 
based on the linear correlation between bilirubin/albumin ratios in fetal blood and in 
amniotic fluid. The slope in Queenan’s and Liley’s chart follows that of the albumin 
concentration in amniotic fluid during gestation.
 
35
Bilirubin/albumin ratios in anemia
3
Introduction
Bilirubin is the degradation product of hemoglobin. Its main configuration in the fetus 
is unconjugated [1]. Unconjugated bilirubin is hydrophobic and tightly but reversibly 
bound to albumin in extracellular fluids [2]. In fetal blood the albumin concentration 
increases between 20 and 35 weeks of gestation [3]. In amniotic fluid the albumin 
concentration initially increases between 20 and 24 weeks, but then decreases 
between 25 and 35 weeks [4,5]. Unconjugated bilirubin is cleared from fetal blood 
over the placenta to maternal blood [6]. Conjugation of bilirubin and excretion through 
the gall bladder or the kidneys are usually not triggered until a few days after birth 
[7,8]. The small amount of conjugated bilirubin that is formed prenatally is probably 
converted to unconjugated bilirubin in the fetal intestines and reabsorbed in the fetal 
circulation [9]. Thus, most of the bilirubin in the fetus and in amniotic fluid is 
unconjugated and bound to albumin.
Since the early 1960s, measurement of the concentration of bilirubin in amniotic fluid 
has been used to predict the severity of fetal hemolytic anemia and to decide on the 
necessity of intrauterine red cell transfusion [10,11]. Recently, noninvasive Doppler 
studies have been introduced to predict fetal anemia [12]. Nevertheless, the Queenan 
chart or the Liley chart still are important diagnostic tools in determining the timing 
of the first intrauterine red cell transfusion because these tests have a high sensitivity 
in this respect [13]. The mechanisms behind these diagnostic tools, however, have 
not been completely unraveled. Yet, understanding the pathways that bilirubin takes 
to distribute to the fetal compartments could lead to a better comprehension of the 
pathophysiology of fetal hemolytic disease, which may further improve our 
management of fetal anemia and neonatal hyperbilirubinemia caused by 
alloimmunization.
We hypothesized that unconjugated bilirubin is equally distributed over the albumin 
molecules that are present in all fetal compartments, including amniotic fluid, before 
it is transported across the placenta toward the maternal blood. Therefore, we 
measured the molar concentration ratios of bilirubin to albumin in fetal blood and in 
amniotic fluid and investigated their correlation. We expected that, if our hypothesis 
were true, there would be a significant linear relation between the two ratios. 
Furthermore, assuming that there would be no difference in binding capacity of 
albumin for bilirubin in the different compartments, the regression coefficient of this 




Leiden University Medical Centre is the national referral center for the treatment of 
fetal anemia in the Netherlands. Our methods for diagnosis and treatment of severe 
fetal alloimmune anemia have been described previously [14]. From January 2001 to 
December 2004, we simultaneously sampled blood and amniotic fluid of singleton, 
nonhydropic, not previously transfused fetuses suffering from severe Rhesus D 
alloimmunization with gestational ages ranging from 20 to 35 weeks gestation. None 
of the fetuses had chromosomal or congenital abnormalities. Bilirubin and albumin 
concentrations were measured in fetal blood samples taken before the first intrauterine 
transfusion and in amniotic fluid samples taken within two days before commencing 
intrauterine transfusion. No additional amniocenteses or cordocentesis were 
performed to collect the data. This study was an addition to the “Diagnostic 
amniocentesis or non-invasive Doppler for the diagnosis of severe fetal anemia” 
study [12], that was approved by the medical ethics committee of the Leiden 
University Medical Center, and for which all woman gave oral or written informed 
consent.
Fetal blood samples were sent to our diagnostic laboratories. In our routine clinical 
chemistry laboratory measurements were made of total bilirubin, conjugated bilirubin 
and albumin on Oya Hitachi p800 modular autoanalyzer (Roche, Mannheim, Germany). 
Also, hemoglobin was measured in our routine hematology laboratory on Sysmex 
XE 2100 (Sysmex, Kobe, Japan). In fetal blood, conjugated bilirubin was subtracted 
from total bilirubin to calculate the concentration of unconjugated bilirubin. These 
measurements are reported in micromolars per liter. Albumin was converted from 
grams per liter to micromolars per liter by multiplying by a factor of 14.4 [15]. Amniotic 
fluid was stored light protected, and delta OD450 was measured within 1 hour after 
sampling, as published before [13]. It has been shown that this method measures 
merely unconjugated bilirubin [16]. The concentration of bilirubin in micromolars per 
liter was established by multiplying the delta OD450 value by a factor of 27.1 [17]. 
The concentration of albumin in amniotic fluid was measured by using a turbidimetric 
method on a Cobas Integra 800 autoanalyzer (Roche, Mannheim, Germany). This 
analysis took place at the section of liquor cerebri analysis in the Department of 
Clinical Chemistry.
Standardized Z scores of hemoglobin (Z-hemoglobin) were defined as the number of 
standard deviations (SDs) that an actual value deviated from the normal mean for 
gestational age. Reference values for hemoglobin were derived from the literature 
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[18]. Pearson correlation coefficients were calculated to study relations between 
different variables, since data were normally distributed. Normality was tested by 
the Kolmogorov-Smirnov test. We considered p<.05 to be significant. The statistical 
software program SPSS 12.0.1 (SPSS Inc., Chicago, IL) was used. The form of the 
relation between the concentration of albumin in amniotic fluid and gestation was 
studied with polynomial regression. The ratio of bilirubin concentration to albumin 
concentration was expressed as a fraction (mol/mol). The relation between the 
bilirubin/albumin ratio in fetal blood and severity of anemia and gestational age was 
studied with linear regression. The same was done for the bilirubin/albumin ratio in 
amniotic fluid. After that, linear regression was performed to study the relation 
between the bilirubin/albumin ratio in fetal blood and the bilirubin/albumin ratio in 
amniotic fluid. Because in clinical practice the bilirubin concentration in amniotic fluid 
is used as a predictor for the amount of hemolysis in the fetal blood, the bilirubin/
albumin ratio in fetal blood was chosen as the dependent variable and the bilirubin/
albumin ratio in amniotic fluid as the independent variable. To study the additional 
influence of gestational age and severity of anemia, a multivariable linear regression 
analysis was performed with the bilirubin/albumin ratio in fetal blood as dependent 
variable and the bilirubin/albumin ratio in amniotic fluid, gestational age, and 
Z-hemoglobin as independent variables. Because bilirubin originates in fetal blood 
and subsequently enters the amniotic fluid, we also performed a multivariable linear 
regression with bilirubin concentration in amniotic fluid as dependent variable and 
bilirubin concentration in fetal blood, albumin concentration in amniotic fluid, and 
albumin concentration in fetal blood as independent variables. Finally, a receiver 
operating characteristic curve was made to determine the optimal cutoff value of the 
bilirubin/albumin ratio in amniotic fluid to predict severe anemia. Fetuses were 
considered severely anemic at Z-hemoglobin of –5 SD or less. The cutoff was 
considered optimal when the sum of the sensitivity and specificity was maximal. The 
sensitivity and specificity of the chosen cutoff value was then compared with the 
sensitivity and specificity of the cutoff line 4 in the Queenan chart and the cutoff line 
2c in the extended Liley chart [12]. 
Results
In the study period, 89 Rhesus D–immunized fetuses received their first intrauterine 
transfusion. Simultaneous sampling of amniotic fluid and fetal blood was performed 




Figure 1 shows the albumin concentration (grams per liter) in amniotic fluid during 
gestation. A cubic regression line fitted the data best (adjusted R2 linear 0.29, adjusted 
R2 quadratic 0.39, adjusted R2 cubic 0.44). An increase in albumin concentration 
between 20 and 24 weeks of gestation and a decrease between 25 and 35 weeks 
of gestation was observed. However, the interindividual variance was large.
Table 1  Maternal and fetal characteristics
Characteristics Mean (Range)
Maternal age (years) 31.5 (20 – 41)
Gravidity 3.3 (1 – 8)
Parity 1.6 (0 – 4)
Last determined antibody titer 1:64 – 1:8000
Last determined ADCC* (%) [19] 55 to more than 80
Gestational age at transfusion (weeks) 29.8 (20 – 35)
Hematocrit at transfusion 0.23 (0.09 – 0.32)
Hemoglobin at transfusion (g/dL) 7.3 (2.6 – 10.8)
* ADCC: Antibody-Dependent Cell-mediated Cytotoxicity assay.
Figure 1  Concentration of albumin (g/L) in amniotic fluid as a function of gestational age (weeks). Mean and its 
95%CI are plotted.
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In fetal blood, the bilirubin/albumin ratio ranged from 0.12 to 0.35. Figure 2 shows the 
bilirubin/albumin ratio in fetal blood plotted against standardized hemoglobin 
concentrations (Z scores). There was a significant correlation of the bilirubin/albumin 
ratio in fetal blood with the severity of anemia (R2 0.23, p=.007). There was no relation 
between the bilirubin/albumin ratio in fetal blood and gestational age (R2 0.00, p=.92).
In amniotic fluid, the bilirubin/albumin ratio ranged from 0.07 to 0.19. Figure 3 shows 
the bilirubin/albumin ratio in amniotic fluid plotted against standardized hemoglobin 
concentrations (Z scores). There was a significant correlation of the bilirubin/albumin 
ratio in amniotic fluid with the severity of anemia (R2 0.37, p<.001). There was no 
relation between the bilirubin/albumin ratio in amniotic fluid and gestational age (R2 
0.004, p=.74).
Figure 4 shows the linear relation between the bilirubin/albumin ratio in fetal blood 
and the bilirubin/albumin ratio in amniotic fluid (R2 0.75, p<.001). Notably, the bilirubin/
albumin ratios in fetal blood were always higher than the bilirubin/albumin ratios in 
amniotic fluid. 
Figure 2  Bilirubin/albumin molar concentration ratio in fetal blood against standardized hemoglobin concentra-
tion (Z scores). Mean and its 95%CI are plotted.
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Figure 3  Bilirubin/albumin molar concentration ratio in amniotic fluid against standardized hemoglobin concen-
tration (Z scores). Mean and its 95%CI are plotted.
Figure 4  Bilirubin/albumin molar concentration ratio in fetal blood against bilirubin/albumin molar concentration 
ratio in amniotic fluid. Mean and its 95%CI are plotted.
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The formula of the regression line shown in figure 4 was as follows: mean 
bilirubin/albumin ratio in fetal blood=0.05+1.4×mean bilirubin/albumin ratio in 
amniotic fluid (95% confidence interval of the constant is 0.01–0.09; 95% 
confidence interval of the regression coefficient is 1.1–1.7). To study the additional 
influence of gestational age and severity of anemia, a multivariable linear regression 
analysis was performed. This showed that the bilirubin/albumin ratio in amniotic 
fluid was still significantly related to the bilirubin/albumin ratio in fetal blood 
(regression coefficient=1.5, p<.001), while there was no significant influence of 
gestational age (regression coefficient=0.00, p=.72) and severity of anemia 
(Z-hemoglobin) (regression coefficient=0.002, p=.59).
Because bilirubin originates in fetal blood and subsequently enters the amniotic 
fluid, we also performed a multivariable linear regression with bilirubin concentration 
in amniotic fluid as the dependent variable. This showed that bilirubin concentration 
in fetal blood (p<.001), albumin concentration in fetal blood (p=.008), and albumin 
concentration in amniotic fluid (p<.001) were all independently related to the bilirubin 
concentration in amniotic fluid. The adjusted R2 of this model was 0.91.
In the receiver operating characteristic curve (ROC curve, not shown), we found that 
0.10 was the optimal cutoff value for the bilirubin/albumin ratio in amniotic fluid to 
predict severe anemia. Table 2 shows the comparison between sensitivities and 
specificities in our study population of this chosen cutoff value and commonly used 
cutoffs in the Queenan and extended Liley charts.
Table 2  Test characteristics of the bilirubin/albumin ratio and Queenan and extended Liley charts to diagnose 
severe anemia*
Cutoff Sensitivity (%) Specificity (%)
Bilirubin/ albumin molar 
ratio 0.10 or greater 86 75
Queenan chart 4 line or greater 82 25
Extended Liley chart 2c line or greater 72 25




In this study, we found a strong linear correlation between the bilirubin/albumin molar 
concentration ratio in fetal blood and this same ratio in amniotic fluid. This is a strong 
argument in favor of our hypothesis that bilirubin is distributed over the available 
albumin in fetal blood and amniotic fluid. However, in contrast with our hypothesis, 
bilirubin is not distributed in an equal manner over the albumin in these fetal 
compartments because the bilirubin/albumin ratio in fetal blood was always higher 
than the bilirubin/albumin ratio in amniotic fluid.
Our curve of the mean amniotic fluid albumin concentration during pregnancy confirms 
previously published data [4,5]. It is also very similar to the cutoff lines of amniotic 
fluid bilirubin concentration during gestation in the Queenan and Liley charts [10,11]. 
This similarity is readily explained by the fact that, in amniotic fluid, bilirubin is bound 
to albumin. Our data are in support of findings by Queenan et al. [11] that linearly 
extending the Liley graph below 22 weeks is not to be advised.
The range of the bilirubin/albumin ratio of 0.12–0.35 that we observed in fetal blood 
was similar to findings of Ritter et al. [20]. In neonates, approximately 30% binding 
of bilirubin to albumin in blood was found [20]. We observed no correlation between 
the bilirubin/albumin ratios and gestational age. Robertson et al. [21] studied albumin 
reserve binding capacity for bilirubin in umbilical cord serum and also found no 
difference between 18 to 42 weeks of gestation.
It is known that there is one strong binding site on albumin for bilirubin and several 
weaker binding sites [2]. Our observed regression coefficient of 1.4 of the regression 
line between the bilirubin/albumin ratios in fetal blood and amniotic fluid may be 
explained by a difference in biochemical qualities between blood and amniotic fluid, 
which influence the binding force of one or more binding sites on albumin. Another 
possible cause for the fact that the bilirubin/albumin ratio in fetal blood was always 
higher than the bilirubin/albumin ratio in amniotic fluid could be a difference in 
competitive binding. Either way, the linear relation between the ratios seems to be 
caused by a constant difference in property between fetal blood and amniotic fluid. 
We speculate that a difference in pH could explain the observed regression coefficient 
of 1.4 between the ratios in fetal blood and amniotic fluid. In vitro experiments have 
shown that 1 mol albumin in serum binds 1.9 mol bilirubin at a pH of 7.4. With a 
decline in pH, albumin will bind less bilirubin [22]. The difference in pH between fetal 
blood and amniotic fluid (respective means of 7.3 and 7.1 in alloimmunized fetuses 
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[23]) could thus be the cause of the observed difference in binding capacity of albumin 
for bilirubin.
Our results contain strong arguments in favor of the theory that amniotic fluid bilirubin 
concentration is determined both by the bilirubin concentration in fetal blood and by 
the albumin concentrations in fetal blood and amniotic fluid. Although urine is the 
principal source of amniotic fluid, it is unlikely that the fetal kidneys are the pathway 
over which bilirubin can enter the amniotic fluid because the concentration of protein 
is 100 times lower in fetal urine than in amniotic fluid. The most likely pathway over 
which bilirubin can constantly be balanced out over the available albumin, therefore, 
seems to be the intramembraneous pathway. The intramembraneous pathway is the 
combined permeable surface that is adjacent to the amniotic fluid. Initially, the fetal 
skin and mucous membranes are an important component of this pathway, and after 
keratinization of the skin, which occurs between 17 and 25 weeks of gestation, the 
main component that remains is the fetal side of the placenta [24]. Knowledge on 
the origin of albumin in amniotic fluid could complete our understanding of this fetal 
physiological mechanism.
Already in 1965, Cherry et al. [25] investigated the correlation of the bilirubin/protein 
ratio in amniotic fluid with the severity of anemia. Sensitivities to predict anemia with 
this ratio were, however, variable [26-28]. The diversity of the methods of 
measurements may explain some of these variable results. Furthermore, false-
negative prediction was reported in fetuses that turned out to be hydropic [29]. 
Nowadays, delta OD450 will not be used clinically, in an alloimmunized patient, when 
hydrops is identified sonographically.
Our findings do have clinical implications. First, understanding the background of a 
diagnostic test gives one the opportunity to understand exceptional cases. In an 
anemic fetus with an abnormal concentration of albumin in the amniotic fluid—for 
example, due to kidney disease, hydramnios, hydrops, or growth restriction—an 
unexpected result in the Queenan or Liley charts may be found. In an anemic fetus 
with a low bilirubin concentration in fetal blood—for example, in Kell immunization—
bilirubin concentration in amniotic fluid may also be lower then expected [30]. Second, 
we observed a significant correlation of the bilirubin/albumin ratio, both in fetal blood 
and amniotic fluid, with severity of anemia. Theoretically, the reliability of the Queenan 
or Liley charts in predicting the degree of hemolysis should be impaired by the wide 
interindividual variation of amniotic fluid albumin concentration. Using the bilirubin/
albumin ratio in amniotic fluid may, therefore, improve our ability to predict the severity 
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of fetal anemia. Also, the bilirubin/albumin ratio does not change during gestation, 
making the test easy to interpret. In our study population, the bilirubin/albumin ratio 
was a more accurate test for diagnosing severe anemia than the Queenan and Liley 
charts. However, the sensitivities and specificities of the Queenan and Liley charts 
in our study were lower than in other studies [12,13]. The suggested cutoff value of 
the bilirubin/albumin ratio of 0.10 should be validated in an independent data set, 
preferably a prospective cohort.
In conclusion, amniotic fluid bilirubin concentration is determined by both the bilirubin 
concentration in fetal blood and by the albumin concentrations in fetal blood and in 
amniotic fluid. The relation between fetal hemolysis and amniotic fluid bilirubin 
concentration is based on the linear correlation between bilirubin/albumin ratios in 
fetal blood and in amniotic fluid. The slope in Queenan’s and Liley’s charts follows 
that of the albumin concentration in amniotic fluid during gestation.
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The study results as presented in chapter 3, are shown here with an addition of 13 
hydropic fetuses. We present 10 mildly hydropic fetuses (semi filled dots) and 3 
severely hydropic fetuses (open dots). Fetuses were classified as mildly hydropic in 
case a distinct rim of ascites and/or pericardial effusion is observed. Fetuses were 
classified as severely hydropic in case an abundant amount of fluid collection with 
skin edema is observed. 
In figure 1 it is shown that the bilirubin to albumin ratio (BAR) in fetal blood increases 
with increasing severity of anemia. However, the severely hydropic fetuses have a 
relatively low BAR in fetal blood. Figure 2 shows the increase in BAR in the amniotic 
fluid with severity of anemia. There is no difference observed between nonhydropic 
and hydropic fetuses. Figure 3 shows the relation of the BAR in fetal blood to the 
BAR in amniotic fluid. In nonhydropic and mildly hydropic fetuses, the BAR in fetal 
blood is always higher compared to that in amniotic fluid. Interestingly though, in the 
severely hydropic fetuses the BAR in fetal blood was almost the same as the BAR 
in amniotic fluid.  
The low BAR in fetal blood in severely hydropic cases could be explained by either 
a diminished hematopoiesis or a dimished binding capacity of albumin in fetal blood. 
Again (as in the addendum of chapter 2), the mildly hydropic fetuses seemed not to 
differ from the nonhydropic fetuses, though severely hydropic fetuses show distinct 
differences. 
In conclusion, it is possible that there is a decrease in binding capacity of albumin for 
bilirubin in fetal blood in severely hydropic fetuses. This might be the result of a 
change of fetal blood pH, a change in albumin posttranslational modifications or a 
change in competitive binding of other ligands to albumin. In addition, it is possible 
that there is an increase in albumin binding capacity in amniotic fluid. It is intriguing 
to consider the rise of protein in amniotic fluid, which has been reported in hydropic 
cases, to be the result of a capillary leakage of fetal albumin into the amniotic fluid. 
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Figure 1  Bilirubin to albumin ratio (mol/mol) in fetal blood in relation to severity of anemia (Z-hemoglobin). Non-, 
mildly and severely hydropic fetuses are depicted.
Figure 2  Bilirubin to albumin ratio (mol/mol) in amniotic fluid in relation to severity of anemia (Z-hemoglobin). 
Non-, mildly and severely hydropic fetuses are depicted.
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Figure 3  Bilirubin to albumin ratio (mol/mol) in fetal blood in relation to that in amniotic fluid. Non-, mildly and 
severely hydropic fetuses are depicted.
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Origin and function of 
amniotic fluid albumin: 




Little is known about the origin of albumin in amniotic fluid. A fetal origin is 
questionable, because of the low concentration of protein in fetal urine and lung fluid. 
A maternal origin of proteins in amniotic fluid was already proposed in the 1970s. 
This review focuses on the possible sources of albumin in amniotic fluid and on the 
pathways for albumin to enter and leave the amniotic fluid in the second and third 
trimester. Based on the available evidence, it is unlikely that the fetus makes a large 
contribution to amniotic fluid albumin. Maternal albumin probably reaches the amniotic 
fluid through the fetal membranes, though the amniotic membrane itself also 
produces albumin. The functions of albumin in amniotic fluid are even less understood. 
Albumin may influence the homeostasis of amniotic fluid volume. Furthermore, intake 
of albumin, and the fatty acids which albumin carries, could be a substantial part of 
fetal nourishment. More knowledge on the mechanisms that determine amniotic 
fluid composition and on the function of albumin in amniotic fluid could provide the 
basis for new fetal therapy strategies. 
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Introduction
Although albumin is the most prevalent protein in amniotic fluid [18;25;26], its origin 
in amniotic fluid remains unclear. Most clinicians in the field of fetal and maternal 
medicine assume that albumin in the amniotic fluid is of fetal origin, though this 
assumption has never been established by research. While the amniotic fluid is mainly 
formed of fetal urine and lung fluid [27], the concentration of protein in fetal urine 
and lung fluid is many times lower than that in amniotic fluid (Table 1). This suggests 
that the albumin in amniotic fluid has a different origin, most likely a maternal source. 
It was already proposed in the 1970s that albumin in amniotic fluid is transported 
from maternal blood to amniotic fluid without passing through the fetal blood [28]. 
Using polymorphisms, multiple larger proteins that are found in the amniotic fluid, 
such as transferrin and alpha1-antitrypsin, have been shown to have a maternal origin 
[29;30]. Finally, the placenta and even the membranes cannot be ignored, and should 
be considered as possible sources of albumin in amniotic fluid.  
The functions served by albumin in amniotic fluid are even more elusive. Albumin is 
a protein that hardly shows any differences between species, underlining its 
importance to sustain life. It surrounds embryo’s in abundance, either when they are 
hatching from an egg or growing inside a uterus. It is the most prevalent serum 
protein with a crucial role in maintaining intravascular osmotic pressure and functioning 
as a carrier protein of numerous substances  [31;32]. One might expect albumin to 
have a similar role in amniotic fluid as it has in the blood. This could imply it has an 
important role in amniotic fluid volume and pressure regulation. Albumin may also 
provide an important contribution to fetal nourishment. When considering the potential 
non-fetal origin of albumin, the amniotic fluid can be seen as a high-energy substance, 
providing prenatal feeding through the gastrointestinal tract. In other words, it could 
provide a kind of fetal “breast” feeding. 
This review considers the current evidence on the origin of albumin in amniotic fluid 
in the second and third trimester of gestation. It will discuss the possible pathways 
from a fetal, a maternal and a placental origin, based on present literature. Due to 
the relative scarcity of human data, results from animal studies will be described 
where human evidence is absent. We will then speculate on the function of albumin 
in amniotic fluid, and will finally propose potential directions for future research.
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Fetal blood as a possible source of amniotic fluid 
albumin
In the embryonic period, production of albumin starts in the yolk sac [33]. By the 
second and third trimester, albumin is probably mainly formed in the fetal liver [34-
36]. There are a number of possible routes by which fetal serum albumin could be 
transferred to the amniotic fluid (see Figure 1). 
Table 1  Normal values of total protein, albumin and AFP concentration in different compartments during 2nd 
and 3rd trimesters of human pregnancy.
Total protein (g/L)‡ Albumin (g/L)‡ Changes during 


















32 weeks and 
then decreases













Fetal lung fluid A [0.006 - 0.4]
[11-13]
? ? ? ?
Fetal urine B [0.04 - 0.1]
[14;15] 
C [0.002 - 0.06]
[16-18]
? ? ?
















‡   Values are given as means. Two values indicate minimum and maximum means at different gestational ages. 
Two values within [ ] indicate the range found in different publications. 
A   tracheal fluid of fetal sheep
B  fetal bladder punctions in obstructive uropathy
C  first voided neonatal urine after birth
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Urine
Urine is the main contributor of amniotic fluid, and as such it is the most obvious 
candidate for the source of amniotic fluid albumin. However, the concentration of 
total protein and albumin in fetal urine is 25 to 750 times lower than the concentration 
in amniotic fluid (Table 1). Table 1 shows the range of reported values for (mean) 
albumin concentration, taken from studies that measured albumin in first voided 
postnatal urine of premature and term neonates. The range of values reported for 
(mean) total protein concentration is also shown, obtained from human fetal bladder 
punctions in obstructive uropathy, in cases with good outcome after birth. Although 
these urine measurements were not obtained in healthy fetuses, it is more likely that 
they overestimate the actual values than underestimate them. The low concentration 
of protein in urine compared to that in amniotic fluid implies that either the amniotic 
fluid is highly concentrated, with water extracted on a daily basis, or that the albumin 
in the amniotic fluid has another source. 
Figure 1  Possible pathways to and from human amniotic fluid in 2nd and 3rd trimester. 
Uterus is depicted, with fetus, placenta and fetal membranes in detail.
Fetus Uterus Placenta Fetal membranes
lu= lung fluid de= decidua cs= chorion stroma am= amniotic 
me= meconium my= myometrium cv= chorial vessels  membrane
mu=  mucous   fc= fetal capillaries ch= chorionic  
membranes   im= intervillous  membrane
sk= ski    maternal blood 
sw= swallowing   sy=  syncytio-    




Note that all pathways are bidirectional except fetal urine and meconium.
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During the 3rd trimester of pregnancy, the amniotic fluid concentrations of several 
proteins decrease [18;22;23]. There are several explanations for this. In the case of 
proteins such as beta2-microglobulin (12 kD), which have a molecular weight lower 
than that of albumin (67 kD), it has been shown that the concentration in first voided 
urine after birth is similar to that in corresponding amniotic fluid [18]. The concentration 
of these proteins in amniotic fluid decreases during pregnancy [18;23]. This suggests 
that tubular resorption increases strongly from 24 weeks gestation onward [18;23]. 
The change in the concentration of low molecular weight proteins in amniotic fluid 
during gestation can thus be explained by renal development. In the case of albumin 
and proteins with higher molecular weight, it has been shown that albumin 
concentration in first voided urine after birth is much lower than in the corresponding 
amniotic fluid [18]. Burghard et al. found that the concentration of postnatal urinary 
albumin and high molecular weight proteins was only 5% and 15% of that in amniotic 
fluid [18]. Gitlin et al. estimated that amniotic fluid albumin was less than 5% of 
urinary origin at term [17]. They calculated that a term fetus would have to produce 
8 litres of urine daily to explain the amount of albumin present in amniotic fluid. Urine 
production and clearance of water (and low molecular weight proteins) are clearly 
not in this order of magnitude [27;37]. A urinary origin of albumin combined with a 
strong daily extraction of water thus seems an implausible explanation for the 
concentration of amniotic fluid albumin. Furthermore, bulk amniotic fluid turnover 
increases strongly during gestation due to an increase in urine production during 
pregnancy [37], as well as an increase in the amount of fluid that is swallowed by 
the fetus [27]. This has led to the conclusion that the decrease of albumin concentration 
in amniotic fluid in the 3rd trimester is a result of a rise in bulk fluid turnover, which 
exceeds the inflow of albumin from a separate source [18;28]. This would indeed 
explain the decrease of amniotic fluid albumin between 25 and 35 weeks of gestation 
and the low concentration of albumin in urine compared to amniotic fluid. It seems 
that the observed changes in amniotic fluid albumin concentration during gestation 
can only be explained by a non-urinary origin of amniotic fluid albumin.  
Another indicator that fetal urine is not the main source of amniotic fluid albumin is 
the ratio between AFP and albumin concentrations. AFP is a fetal protein with a 
molecular weight similar to that of albumin (AFP, 70 kD; albumin, 67 kD). In normal 
pregnancies, the fetal urine to fetal blood concentration ratio is roughly similar for 
AFP and albumin [38]. However, at term, as can be derived from Table 1, the 
amniotic fluid to fetal blood concentration ratio for AFP is 30 times smaller than that 
of albumin. This relatively high concentration of albumin, implies a mainly non-urinary 
source of amniotic fluid albumin. In pregnancies complicated by congenital nephrosis, 
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fetal proteinuria leads to markedly raised amniotic fluid AFP [39]. Amniotic fluid 
albumin, however, is only slightly elevated or even normal [40]. Thus, although it is 
probable that AFP in amniotic fluid originates mainly from fetal urine, it is likely that 
the albumin in amniotic fluid has another source. 
Lung fluid
Lung fluid is the second largest contributor to amniotic fluid. It is estimated that 
around 15% of the daily production of amniotic fluid is attributable to lung fluid [27]. 
Although more lung fluid is produced, about half of it is immediately swallowed [41]. 
However, total protein concentration in fetal lung fluid is many times lower than in 
the amniotic fluid (Table 1). A number of experiments have been conducted using 
ovine fetuses to study fetal lung fluid production. When radioactively labelled albumin 
was injected, hardly any was found to pass from fetal blood to lung fluid [13]. 
Furthermore, it was shown that chloride is actively secreted by fetal lungs and, along 
with it, a fluid with a protein concentration much lower than that in fetal lung interstitial 
fluid [42;43]. Of course, care should be taken when interpreting these above 
mentioned findings, as they were all derived from studies in ovine fetuses. However, 
current knowledge of human fetal lung physiology shows similar results to those in 
ovine studies. For example, using pulmonary Doppler ultrasonography, human fetal 
lung fluid outflow was shown to increase until 36 weeks of gestation [44], similar to 
measurements in ovine fetuses [45]. To our knowledge, no data exists on the 
concentration of albumin in human fetal lung fluid. Unfortunately, neonatal 
bronchoalveolar lavage measurements can not be compared with the fetal situation, 
since lung fluid production is strongly decreased after birth mainly due to a strong 
decrease in active chloride secretion [43]. To conclude, though little is known on 
human fetal lung fluid composition, based on ovine experimental studies, it is unlikely 
that lung fluid is a significant contributor to amniotic fluid albumin.
Intestines 
Fetal intestines are another possible source of amniotic fluid albumin. It is often 
assumed that meconium is voided into the amniotic fluid only just before or during 
birth. However, during fetoscopy, small amounts of meconium have been observed 
as early as the early second trimester of gestation. In fact, intestinal enzymes are 
present in amniotic fluid throughout pregnancy [46]. However, fetal continence for 
meconium seems to increase markedly after 18 weeks of gestation [47]. It has also 
been shown that after 18 weeks, intestinal enzymes in amniotic fluid decrease 
significantly [48-50]. Furthermore, it has been shown between 35 and 42 weeks 
gestation that there is  no significant difference in albumin concentration between 
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amniotic fluids that contain meconium and those that do not [21]. Finally, in an ovine 
experimental study, iatrogenic jejuno-ileal atresia did not alter albumin concentration 
in amniotic fluid [51]. In conclusion, although there may be an intestinal contribution 
to amniotic fluid albumin before 18 weeks, it is very unlikely that there is a significant 
contribution in the late 2nd trimester or the 3rd trimester. 
Skin
The skin is another possible pathway through which albumin could permeate. In 1969, 
Lind et al. described microvilli on human fetal skin at 14 weeks gestation [52]. Such 
microvilli are also present on amniotic membrane [53;54] and indicate an important 
transport function. However, a marked change takes place shortly after 14 weeks. 
From 25 weeks gestation, human fetal skin consists of multiple layers and is 
keratinised, making it much less permeable for water and solutes [52;55-57]. In 
conclusion, it is unlikely that fetal skin is a significant contributor to amniotic fluid 
albumin in the second half of pregnancy.
Intramembraneous pathway
Finally, the so-called intramembraneous pathway could contribute to the albumin in 
the amniotic fluid. This is a pathway between the fetal blood and the amniotic fluid, 
which is thought to explain important fluid shifts in ovine fetuses, and which probably 
also exists in humans (see Figure 1) [58]. Brace and Gilbert introduced this possible 
pathway, pointing out that not all uptake of amniotic fluid was due to swallowing, but 
that part of the reabsorption must take place through the membranes. Therefore, 
they hypothesised a kind of lymphatic drainage, between the amnion and chorion 
leave, draining amniotic fluid towards the fetal blood vessels on the fetal surface of 
the placenta. In ovine pregnancy, an anatomic substrate for fluid drainage is present 
in the form of micro blood vessels between the amnion and chorion leave. Brace and 
Gilbert named this the intramembraneous pathway. In humans, though, there are no 
micro blood vessels between the amniotic and chorionic membranes, but there is a 
large surface area of fetal blood vessels present in the umbilical cord and at the fetal 
surface of the placenta adjacent to the amniotic fluid. Using a mathematical model, 
Mann et al. calculated that human intramembraneous flow of water must be around 
390 ml daily [59]. The term intramembraneous pathway has subsequently been 
proposed for the combination of fetal skin, the mucous membranes (mainly oro-nasal 
saliva), the umbilical cord surface, and the fetal side of the placenta [27]. 
The components of the intramembraneous pathway could all contribute to the build-
up of albumin concentration in amniotic fluid. The contribution of human fetal skin 
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has already been discussed. The contribution of mucous membranes in the human 
situation is unknown. In 3 kg ovine fetuses, fluid secretions from the head amounted 
to 25 ml daily [27]. The contribution of the umbilical cord is also unknown, but depends 
on the transport characteristics of Wharton’s jelly. Since Wharton’s jelly contains 
mucopolysaccharides, this may facilitate the transport of some amniotic fluid solutes 
like bilirubin [28]. In fact, albumin has been shown to pass through ovine umbilical 
cords in vitro [28]. Finally, the main contributor of the intramembraneous pathway is 
expected to be the fetal surface of the placenta. Both the chorionic tissue and the 
chorial blood vessels could transport fetal serum albumin to the amniotic fluid. 
However, animal research has not yet demonstrated albumin transport from the fetus 
to amniotic fluid through this pathway, but has instead shown an albumin transport 
in the opposite direction [60;61]. In view of this, it is unlikely that the intramembraneous 
pathway is a significant contributor to amniotic fluid albumin.
Several investigators have studied the dynamics of transport between amniotic fluid 
and fetal blood through the intramembraneous pathway. Passive diffusion of solutes 
seems to occur in both directions over the intramembraneous pathway, limited only 
by solute size [62]. However, passive diffusion only accounted for a minor part of the 
flow over the intramembraneous pathway. The majority of intramembraneous flow 
seems to be due to bulk flow of water and solutes, which is only explainable by 
unidirectional transport, in the form of active vesicular transport [62-64]. This 
hypothesis was developed in part due to several studies that used albumin tracers 
to investigate intramembraneous flow. In 2002, in an ovine study by Faber et al., 125I 
labelled albumin was injected into the amniotic fluid [60]. All urine and lung fluid was 
diverted and fetuses were made unable to swallow. They found that 125I-albumin was 
cleared from amniotic fluid at a rate of 25-30 ml/h bulk flow. In addition, after 125I 
labelled albumin was injected in fetal serum, hardly any 125I-albumin appeared in the 
amniotic fluid after 30 hours. Previously, Mann et al. had performed a similar study 
and obtained comparable results [61]. Besides radioactively-labelled albumin, they 
also injected radioactively-labelled creatinin into the amniotic fluid. They found that 
creatinin clearance from amniotic fluid was greater than albumin clearance, 5 hours 
after injection. Notably, they found a higher radioactivity in fetal blood compared to 
maternal blood. However, caution should be made in extrapolating data from ovine 
studies. Osmolality is higher in ovine than in human amniotic fluid, and differences 
in osmolality and composition suggest that human and ovine amniotic fluid have 
different regulating mechanisms [65]. Nonetheless, vacuolation was recognised in 
human amnion with electron microscopy [54;66], which might support the hypothesis 
of active vesicular transport. It has also been proposed that aquaporins play an 
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important role in intramembraneous flow [67]. These are small transcytotic channels 
that transport water and in some cases small molecules such as 0.1 kD creatinin. 
However, aquaporins are unable to transfer larger 67 kD albumin. Human studies on 
the intramembraneous pathway are scarce. In 1972, Gitlin et al. injected radioactively-
labelled protein into human amniotic fluid in 2 cases after the occurrence of intrauterine 
fetal death [17]. Birth took place 2 days after administration. As would be expected, 
no 125I-albumin was retrieved in the stomach. Nonetheless, 10% of the injected 
125I-albumin was still cleared from the amniotic fluid. This was believed to have taken 
place through the fetal membranes, since the highest radioactivity was registered in 
the membranes. After birth, some radioactivity could also be measured in the cord 
blood and some in the maternal blood. In conclusion, it does not appear that albumin 
is transported from fetal blood to amniotic fluid through the intramembraneous 
pathway in significant amounts. It is, however, plausible that the intramembraneous 
pathway is in part responsible for the transport of amniotic fluid albumin to the fetal 
blood.  
Summary
Based on the available evidence from the literature, it is unlikely that the fetus 
contributes significantly to the amniotic fluid albumin. Data from human and animal 
experiments seem to rule out fetal urine, lung liquid, skin or intestines as a large 
source of albumin. Finally, studies on the intramembraneous pathway have shown 
uptake of albumin rather than excretion into the amniotic fluid. 
Maternal blood as a possible source of amniotic fluid 
albumin
Most clinicians think the transfer of molecules between mother and fetus takes place 
exclusively from maternal blood to fetal blood over the trophoblast. However, there 
are other possible pathways that albumin could take to leave the maternal blood and 
build up a concentration in the amniotic fluid. 
Via fetal blood
First of all, the possibility should be considered that albumin is transferred via the 
trophoblast from maternal to fetal blood, after which it enters the amniotic fluid. In 
1997, Malek et al. performed a study in a dually-infused human placental lobe [68]. 
14C-labelled albumin and IgG were injected into the maternal side of the placental 
lobe. Only small traces of albumin were retrieved at the fetal side of the placenta. 
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After 1 hour, this low concentration of albumin remained constant for the study period 
of 4 hours. In contrast, after an internalization phase of 2 hours, the concentration of 
IgG kept increasing markedly in the fetal blood. Although albumin and IgG are both 
bound by the so-called neonatal Fc receptor (FcRn), this phenomenon could be 
explained by the observation that a specific Fc receptor (FcgammaRIIb) is present in 
fetal capillary endothelium, which can transfer IgG into the fetal blood, but not albumin 
[69]. In the previous chapter, we already saw the unlikelihood that fetal serum 
accounts for significant amounts of the albumin in the amniotic fluid. In conclusion, 
it is unlikely that maternally derived albumin would be transported via fetal blood and 
then contribute significantly to amniotic fluid albumin. 
There are, however, other possible pathways that albumin could take to move from the 
maternal compartment to the amniotic fluid, without first entering the fetal blood. 
Transmembraneous pathway
The transfer of albumin from maternal blood to amniotic fluid and vice versa can 
theoretically take place through the amnion and chorion leave. The exchange of fluid 
and solutes through the amniotic and chorionic membrane towards the decidua 
parietalis and the maternal uterus is frequently referred to as the transmembraneous 
pathway (see Figure 1). In ovine experiments, the transmembraneous flow of water, 
in second and third trimester, seems to be directed from amniotic fluid towards the 
decidua. It is estimated that at term, about 1% of all outward flow from the amniotic 
fluid takes place via the transmembraneous pathway [70]. This is in contrast to early 
pregnancy, when the chorion is the major pathway for inward flow of water and 
solutes into the coelomic fluid [71]. In 20 and 42 day old human embryos, albumin 
has been histochemically shown to be present in the yolk sac, chorion stroma and 
amnion [72]. In 1982, Wang et al. identified breaks in the basement membrane in 
fresh full term human amnion with electron microscopy. Based on this finding, and 
the fact that intercellular occluding junctions are absent in the amnion, they proposed 
the possibility of a transmembraneous transfer of proteins into the amniotic fluid [53]. 
In 1983, Wang and Bartels supported this hypothesis with the finding that the 
intercellular channels in human chorion also contain very few occluding junctions, 
making a paracellular route for proteins plausible [73;74]. In conclusion, the 
transmembraneous pathway is a possible route for the build-up of amniotic fluid 
albumin concentration.  
 
Via placental tissue 
Finally, though it is seldom considered, the placental tissue could serve as a direct 
pathway. It is theoretically possible that a direct exchange takes place from the 
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maternal blood in the placenta, through the chorion tissue, through the amniotic 
membrane on the fetal side of the placenta, to the amniotic fluid (see Figure 1). 
Passive diffusion of molecules through the placenta can only take place up to 0.6 kD 
[75]. Active transport to the amniotic fluid, however, may be possible, through this 
part of the intramembraneous pathway. For example, an ovine experimental model 
suggested that there is an active transport of glucose and lactate through the 
intramembraneous pathway into the amniotic fluid [63]. It is therefore conceivable 
that there is also an active transport of albumin through the fetal side of the placenta. 
Different receptors, for example FcRn, could be involved in binding albumin [76]. 
Binding receptors can theoretically either concentrate albumin on the cell surface, 
induce formation of endocytose vesicles, or they can save albumin from degradation 
in the acid environment of the endosomes, thus recycling albumin back to the apical 
cell surface or facilitating transcytotic transport. Though several receptors that can 
bind albumin have been shown to be present in the human placenta [77-79], it is not 
known to what extent these receptors contribute to the transport of albumin through 
the placenta. In 2006, Lambot at al. showed that in the term human placenta, uptake 
of maternal albumin takes place in the trophoblast, via clathrin-mediated vesicular 
transport [78]. In their study, however, a quarter of the albumin was rapidly recycled 
towards the maternal side of the trophoblast. Most of the internalized maternal 
albumin was degraded, and it did not seem to reach the villous stroma or cross the 
endothelium of fetal capillaries. However, this may not rule out a pathway for albumin 
directly through the chorion stroma in the placenta to the amniotic fluid. Lambot et 
al. suggested that 150 grams of albumin enters the trophoblast layer daily [78]. Even 
if most of this is recycled to the maternal blood or degraded, a significant amount 
could still remain, which could be transported through the placenta to the amniotic 
fluid. It is worth noting that a study of adult mice showed that FcRn saved as much 
albumin from degradation in the endosomes as the liver produced daily [80]. It is 
imaginable that such a recycling mechanism also takes place on the fetal side of the 
placenta. Thus, after uptake of amniotic fluid albumin via vesicular transport in the 
intramembraneous pathway, albumin may be released back into the amniotic fluid, 
thus increasing its concentration there. In conclusion, we can only speculate on the 
contribution of maternal albumin transferred via placenta tissue to the amniotic fluid. 
Recycling of amniotic fluid albumin on the fetal side of the placenta should also be 
considered. 
Studies indicating a maternal origin
The first indication for the maternal origin of amniotic fluid albumin came from several 
studies using radioactively-labelled albumin. In an experiment by Gitlin et al. in 1964, 
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131I labelled albumin was injected into human maternal blood at term [81]. After 3 to 
9 hours, radioactivity and albumin concentration were measured in maternal blood, 
fetal blood and amniotic fluid. A 3 to 5 times higher specific activity per mg albumin 
was found in amniotic fluid than in fetal blood. In contrast, radioactively-labelled IgG, 
injected into maternal serum, showed a 2.5 times lower specific activity in amniotic 
fluid than in fetal blood after 4 hours. A month after the injection of the 131I labelled 
albumin (25 and 32 days), there was no protein-bound radioactivity left in the amniotic 
fluid, although there was still radioactivity present in fetal and maternal blood. In a 
comparable study, performed by Dancis et al. in 1961, radioactively-labelled albumin 
was injected into human maternal blood at three months gestation [82]. After 24 
hours, radioactivity in amniotic fluid was lower than that in fetal blood.  However, 
since radioactivity was only measured per ml and not per mg albumin in this study, 
specific activity per mg albumin may have been higher in amniotic fluid, as was found 
by Gitlin et al. Theoretically, measurement of radioactivity per mg is a preferable 
measure, since it reflects the proportion of maternally derived albumin compared to 
fetally produced albumin, ignoring the difference of the fluid volume in which the 
tracer is dissolved. In 1986, Tomoda et al. published a study where 125I-labelled 
albumin was injected into the amniotic fluid of ovine fetuses [83]. It was shown that 
as the fetus digested the albumin, most radioactive iodine was spliced from the 
albumin and cleared via the placenta to the mother, and was subsequently retrieved 
in maternal urine. Fetal urine was measured for 9 days, using a catheter, before 
recycling it to the amniotic fluid. Hardly any 125I re-entered the amniotic fluid through 
fetal urine. Based on Gitlin et al.’s findings, in 1975, Sutcliffe argued that if the albumin 
in the amniotic fluid had been of fetal origin, its specific activity would not have 
exceeded that in the fetal serum. Thus, he concluded, most of the albumin in amniotic 
fluid at term must be of maternal origin [28]. Dancis et al. came to the opposite 
conclusion, but it is not possible to say whether this is because the transfer 
mechanism is different at different gestational ages (Dancis’ study was conducted 
at three months gestation, whereas Gitlin’s study was conducted at term), or whether 
it is due to the difference in measurement method (per ml instead of per mg). Finally, 
Tomoda et al. pointed out that the results of studies with radioactively-labelled albumin 
should be interpreted with caution since 125I-albumin can be spliced when digested 
by the fetus. Dancis et al. also addressed this problem, pointing out that the possibility 
that radioactive iodine is spliced in the placenta can not be ruled out. This may explain 
why hardly any protein-bound radioactivity was measured in the amniotic fluid after 
25 or more days. In conclusion, radioactive labelling studies at term endorse the idea 
that maternal albumin is transported directly from maternal blood to the amniotic 
fluid without passing through fetal blood.
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The second indication for the maternal origin of amniotic fluid albumin is the fact that 
proteins with a molecular weight of over 260 kD are not detected in amniotic fluid 
[25;28]. This suggests that proteins enter the amniotic fluid by ultrafiltration and that 
they are only able to permeate the fetal membranes when they are below a certain 
molecular weight. One striking example is haptoglobin 1-1, with a molecular weight 
of 85 kD, which is found in amniotic fluid, whereas the other forms 2-1 and 2-2, with 
a molecular weight of over 260 kD, are not. Thanks to the difference in the isoforms 
of haptoglobin, it has been possible to prove the maternal origin of haptoglobin 1-1 
in amniotic fluid in some cases [84]. Since albumin has a molecular weight of 67 kD, 
it should be able to permeate the membranes. In 1960, Abbas et al. found that at 
term, the electrophoretic protein pattern of amniotic fluid was very similar to that 
obtained by dialysing maternal serum through the fetal membranes [85]. In conclusion, 
based on its molecular weight, it is likely that albumin enters the amniotic fluid by 
passive diffusion through the membranes. 
The third indication for the maternal origin of amniotic fluid albumin comes from 
measurements of protein concentration ratios. It has been hypothesised that if serum 
proteins enter the amniotic fluid by ultrafiltration, then proteins of similar molecular 
weights will diffuse into the amniotic fluid at approximately the same rate. Thus, the 
relative concentration of proteins would be similar in two compartments. Derrington 
et al. investigated the ratio of transferrin to albumin and found that, at term, the ratio 
of transferrin to albumin in amniotic fluid was more similar to that in maternal blood 
than to that in fetal blood [87]. Transferrin has already been shown to be of maternal 
origin by comparing polymorphisms of the protein in amniotic fluid and in fetal and 
maternal blood [29]. Both Sutcliffe et al. and Johnson et al. studied the change in 
protein concentration during the course of pregnancy, comparing the concentrations 
of proteins in amniotic fluid to the concentrations in fetal and maternal serum [38;86]. 
The albumin concentration ratios during pregnancy were similar to the ratios of 
proteins like orosomucoid and Gc-globulin that are of proven maternal origin, and 
were very different from the ratios of AFP, which is of proven fetal origin. 
Several of the studies discussed above were already mentioned in an extensive 
review published in 1975 entitled “The nature and origin of the soluble protein in 
human amniotic fluid,” in which R.G. Sutcliffe concluded that albumin in amniotic 
fluid must be, to a large extent, of maternal origin [28]. 
Summary
Based on the available evidence, it is likely that amniotic fluid albumin is, to a 
significant degree, of maternal origin. From in vivo and in vitro experiments, it seems 
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probable that albumin is transported via the transmembraneous pathway. It is not 
known to what extent the fetal side of the placenta contributes to maternally derived 
albumin transport or to recycling of amniotic fluid albumin.
Placenta or fetal membranes as a possible source of 
amniotic fluid albumin
Another possible explanation for the relatively high concentration of albumin in 
amniotic fluid compared to fetal urine and lung fluid, which are the main sources of 
amniotic fluid, is that the placenta or fetal membranes produce the albumin that 
enters the amniotic fluid. 
Placenta
Several studies have investigated the synthesis of albumin in the placenta. In baboon 
fetuses, no albumin mRNA was detected in the placenta or the amniotic membrane 
[36]. In the term human placenta, however, McKinnon et al. identified albumin mRNA 
in the syncytiotrophoblast by RT-PCR and albumin protein by immunohistochemistry 
[87]. Similarly, AFP synthesis was detected in the trophoblast, though only in the first 
trimester and not in the term human placenta [88]. In conclusion, albumin does seem 
to be synthesized in the placenta, but it is not known to what extent this reaches the 
amniotic fluid.
Fetal membranes
To our knowledge, there are no reports on the synthesis of albumin in the chorionic 
membrane. However, the amniotic membrane itself is a plausible contributor to 
amniotic fluid albumin. The amniotic membrane consists of a single layer of epithelial 
cells on a thicker basement membrane and a collagen spongy layer containing 
mesenchymal cells. Albumin gene expression has been observed in human amniotic 
epithelial cells [89]. Moreover, Takashima et al. demonstrated that these cells can 
synthesize and excrete albumin at term. This synthesis was 30 fold greater in intact 
amnion compared to a cultivated monolayer of amniotic epithelial cells [90]. 
Furthermore, albumin mRNA expression was observed in mesenchymal cells from 
human amniotic membrane. However, production of albumin and AFP only increased 
significantly when these cells were induced to differentiate to hepatocyte type cells 
in vitro [91]. In conclusion, it is likely that the amniotic membrane contributes to the 




Based on the available literature, it is not known if the placenta or the chorionic 
membrane contribute to amniotic fluid albumin. It is, however, likely that amniotic 
fluid albumin is to a certain extent of amniotic membrane origin.
The function of amniotic fluid albumin
Human serum albumin is a relatively small protein that accounts for around 75% of 
protein molecules and about half of total protein mass in the plasma of healthy adults 
[32]. In fetal blood, albumin forms an even larger fraction of total protein (Table1). 
Because of its relatively large contribution to the plasma protein pool, albumin is 
responsible for approximately 75% of plasma colloid oncotic pressure in adult serum 
[32]. Besides this, its main function is to act as a carrier protein: e.g., for fatty acids, 
steroid and thyroid hormones, calcium, nitric oxide, bilirubin, and numerous types of 
toxins and drugs [31;92]. Serum albumin has other functions, among them an 
antioxidant function and an enzymatic function, and it also modulates inflammatory 
response [32]. 
Volume regulation
We can only speculate about the function of albumin in amniotic fluid. As in blood, 
albumin in amniotic fluid is the major component of total protein [18;25;26]. Albumin 
in amniotic fluid may also have a function in maintaining osmotic pressure, and it 
could therefore have a regulatory function in the volume and pressure of the fluid. 
Albumin concentration in maternal blood, has been shown to influence human 
placental lactogen secretion by the placenta [93;94]. Lactogen receptors in the 
amniotic membrane, in turn, may be involved in amniotic fluid volume regulation [95]. 
Albumin may also influence vesicular transport in the intramembraneous pathway, 
since it has been shown that albumin concentration regulates caveolin-1 production 
in the human liver [96]. Caveolin-1 is essential in forming caveolae and has been 
found in fetal endothelium in the human placenta [97]. 
Carrier protein
Albumin may play an important part in recycling and detoxifying solutes in amniotic 
fluid. As a carrier protein, it binds numerous solutes that enter the amniotic fluid and 
it can hold toxins, rendering them harmless [31]. Uptake and degradation can then 
take place in the fetal gastrointestinal tract or in the fetal side of the placenta.
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Nutrition
Considering its non-fetal origin, the albumin in amniotic fluid may have another 
important function. We know that the fetus at term swallows and digests about 80% 
of amniotic fluid every 24 hours [27]. In a study by Gitlin et al. in 1972, radioactively-
labelled proteins (such as 125I-albumin) were injected into the amniotic fluid, hours or 
days before birth [17]. In live fetuses, two thirds or more of the amniotic fluid volume 
was cleared of protein per day and most of this could be retrieved in the stomach 
after birth. Swallowing prior to birth can thus add significantly to fetal protein intake. 
Albumin could serve as an extra source of amino-acids and energy, especially 
considering its carrier function of fatty acids in aqueous solution. Fetuses that lack 
this extra source because of an oesophageal or intestinal obstruction are more often 
growth restricted. In a fetal rabbit experiment, oesophagus ligation restricted growth 
by 10 to 15% [98]. A retrospective study in fetuses with gastro-intestinal malformations 
showed that 38% were small for gestational age [99]. This growth retardation was 
found to be most significant in the last weeks of gestation [100]. Since more than 
90% of fat deposition in the fetus occurs in the last ten weeks of pregnancy [101], 
a large amount of fatty acid transfer is required during this period. 
Regulation of amino acid uptake from mother to fetus is not yet fully understood 
[102]. If the albumin in amniotic fluid is indeed of maternal origin, it is clear this would 
contribute to daily amino- and fatty acid uptake. Also, it is possible that fatty acids or 
other ligands are brought into the amniotic fluid through the fetal membranes, along 
with albumin. Maternal diet has already been shown to influence fatty acid composition 
in the amniotic fluid and fetal intestinal membrane in rats [103]. Further, even if the 
albumin in amniotic fluid has an amniotic membrane or placental origin, its amino-
acids must still come from the mother. Placental insufficiency might then be not just 
a matter of diminished transport but also of diminished production of albumin. In 
conclusion, it is important to realize that the fetal membranes could actively participate 
in the exchange processes between the maternal and fetal compartment.  
Summary
Based on the known functions of albumin in blood, it is probable that albumin in 
amniotic fluid influences the homeostasis of amniotic fluid volume. It is also possible 
that it functions as a carrier protein, for example for fatty acids. Finally, it is very likely 




To date, research has not brought forth solid conclusions regarding the origin of 
albumin in amniotic fluid. In recent years, the proteins in the amniotic fluid have again 
been studied extensively, this time in the field of proteomics [25;26;104]. However, 
the possible maternal origin of these proteins has hardly been addressed. Research 
on the transport mechanism that regulates albumin concentration in amniotic fluid 
may have wider implications, ultimately leading to new treatment modalities involving 
the amniotic fluid. 
Albumin polymorphisms
In the case of a maternal or paternal abnormality or polymorphism of albumin, the 
type of albumin in amniotic fluid could be compared to that in maternal serum to 
establish evidence for the fetal or maternal origin. There are several polymorphisms 
known in human albumin that could easily be measured with tandem mass 
spectrometry [105]. Unfortunately, polymorphisms are rare, with frequencies reported 
to lie between 1 in 1700 to 1 in 3000 in humans [106;107]. However, in case an 
amniocentesis would be performed in a mother with a known albumin polymorphism, 
it would become possible to measure the proportion of maternal and fetal contribution 
to amniotic fluid albumin at a given gestational age.
Albumin tracing
Labelling studies could be designed without the use of radioactivity or toxins, to study 
the tracer dynamics of maternally injected albumin into the fetal blood and amniotic 
fluid. For example, stable isotope tracers could be measured with gas chromatography/
mass spectrometry (GC/MS) or GC-combustion-isotope ratio mass spectrometry 
(GC-C-IRMS). This method has already been used to study surfactant metabolism in 
premature neonates [108]. Intrauterine transfusion would be a unique situation where 
simultaneous samples could be obtained from maternal blood, fetal blood and 
amniotic fluid at different gestational ages.
Albumin synthesis
The production of albumin in the placenta, and chorionic and amniotic membranes 
could also be investigated. Real time-PCR of mRNA and immunohistochemistry of 
albumin and its precursors, can be compared at different gestational ages [87;88]. In 
addition, mesenchymal stem cells or other free floating cells that are present in the 
amniotic fluid could be considered as a source of albumin. 
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Albumin transport
The transport mechanisms through the chorion and amnion can be studied, to gain 
insight into the pathways that albumin takes and the functioning of the intra- and 
transmembraneous pathway in humans. When doing this, a bidirectional transfer of 
albumin must be considered. Passive diffusion and active excretion, as well as active 
vesicular transport should be considered. Albondin, caveolin, megalin, cubilin or 
clathrin-mediated vesicle transport and macropinocytosis can be studied in human 
in vitro placenta and membrane models [78]. Finally, the possibility should also be 
considered that albumin is recycled after vesicular transport, due for example to 
binding to FcRn [80].
Poly- and oligohydramnios
Another possibility to gain insight into the intramembraneous pathway, is to investigate 
the concentration of amniotic fluid albumin in poly- and oligohydramnios, of different 
types of causes. Since these pathological situations represent a dysfunction of the 
homeostatic properties of the intramembraneous pathway, comparison between 




Transamniotic feeding of amino- and fatty acids may be a complement to transplacental 
feeding and can therefore be considered in investigations on intrauterine growth 
restriction and fetal therapy for this problem. Since the importance of prenatal nutrition 
on adult metabolism has become apparent in recent years, transamniotic feeding 
should also be considered in the research on the developmental origins of health and 
disease. 
Conclusion
From the currently available evidence, it appears that the fetus does not make a large 
contribution to albumin in the amniotic fluid in the second and third trimesters. It 
seems that a significant amount of the albumin in the amniotic fluid is of maternal 
origin, and this maternal albumin probably reaches the amniotic fluid through the fetal 
membranes. In addition to passive diffusion, it is possible that there is a form of active 
transport or even recycling of albumin over the intra- or transmembraneous pathway. 
The amniotic membrane itself also produces albumin. At present, we do not know 
with certainty what the relative contribution is of each of the possible sources for 
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amniotic fluid albumin. These relative contributions presumably change during the 
course of the pregnancy. 
The albumin in amniotic fluid has a number of possible functions. These include 
volume regulation and transport of either toxins or nutrients. Intake of non-fetal 
albumin, and the fatty acids which albumin carries, could be a substantial part of fetal 
nourishment.
Different suggestions have been proposed in this review to investigate the origin, 
the transport mechanisms, and the function of albumin in amniotic fluid. This could 
lead to the development of new fetal therapy strategies, including relatively simple 
measures for otherwise hard-to-treat conditions such as poly- and oligohydramnios 
and intrauterine growth restriction.
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The pathophysiology of fetal hydrops is still unclear. One factor that is believed to 
contribute to hydrops is hypoalbuminemia. Our research question was whether 
hypoalbuminemia in immune hydrops is causative or a secondary effect.  
Study design
Between 1987 and 2005, fetal blood samples were taken at the first fetal blood 
transfusion in 224 Rh-D alloimmunized pregnancies. We measured hemoglobin 
concentration and albumin concentration and assessed the severity of hydrops. 
Results
A decrease in albumin concentration occurred only below a hemoglobin deficit of >8 
SDs in 27 fetuses. In 161 nonhydropic, 44 mildly hydropic, and 19 severely hydropic 
fetuses, albumin concentrations were >2 SDs below the mean for gestational age 
in 6%, 14%, and 63%, respectively. 
Conclusion
Our finding that most fetuses with immune hydrops have an albumin concentration 
within the normal range (71%) suggests that hypoalbuminemia is unlikely to cause 





The overall prognosis of fetal hydrops is poor, with a perinatal mortality rate between 
50% and 98% [1]. In fetuses with severe alloimmune anemia, the severity of hydrops 
is a major determinant for the prognosis [2]. Also, in many other fetal diseases, the 
presence or absence of hydrops has a major influence on the chances for survival. 
However, the mechanisms in fetal disease that lead to hydrops remain unclear. 
Several hypotheses regarding the pathophysiologic condition of fetal hydrops have 
been suggested [3]. Extravascular accumulation of fluid can be caused by decreased 
intravascular osmotic pressure, increased intravascular hydrostatic pressure, or 
lymphatic flow compromise. 
Decreased intravascular colloid osmotic pressure can be caused by hypoalbuminemia. 
Leaking of albumin through endothelium may occur as a result of hypoxia-mediated 
damage [4]. Alternatively, decreased albumin production could be the result of fetal 
liver dysfunction (eg, in chronically anemic fetuses with increased extramedullary 
erythropoiesis or portal hypertension) [5]. Phibbs et al. [6] found, in severely anemic 
neonates, a relatively increased plasma volume that is associated with low albumin 
concentrations (Albs) and hydrops. Furthermore, elevation of umbilical venous 
pressure in the presence of decreased colloid osmotic pressure might be the onset 
of extravasation of fluid [7]. Fetal cardiac decompensation or increased intrathoracic 
pressures (eg, because of lung tumors or chylothorax) lead to increased central 
venous pressures and obstruction of lymphatic emptying, which results in the 
development of hydrops [8-10]. Finally, various mediators, such as atrial natriuretic 
factor, influence cardiovascular adaptation to anemia and hypoxia [11]. 
With the assumption that hypoalbuminemia is a major contributor to the development 
of hydrops, several investigators have tried to treat fetal hydrops using albumin 
infusions [12,13]. A better understanding of the cascade of events that lead to the 
development of hydrops may allow much needed advances in prenatal preventive 
or therapeutic modalities. This study was designed to evaluate the role of 




We searched our fetal database for all Rh-D alloimmunized pregnancies that 
underwent intrauterine blood transfusion between 1987 and June 2005. Fetal 
hemoglobin concentration (Hb) and Alb from the first fetal blood sampling in each 
pregnancy were recorded prospectively. We excluded fetuses with structural or 
chromosomal anomalies and intrauterine growth restriction or infection and 
pregnancies with incomplete data. 
From the ultrasound report at the time of fetal blood sampling, the presence or 
absence of hydrops was obtained. Hydropic fetuses were classified as mild or severe, 
by the criteria described by van Kamp et al. [2]. Briefly, mild hydrops was defined as 
the presence of a distinct rim of ascites, with or without pericardial effusion; severe 
hydrops was defined as the presence of a more abundant amount of fluid collection, 
usually ascites, with skin edema. 
The measured values for Hb and Alb were plotted on previously published standard 
reference ranges. For Hb, the reference range of Nicolaides et al. [14] was used. The 
nomogram that we used for fetal Alb was from Takagi et al. [15]. We calculated 
gestational age independent Z-values to evaluate the correlation between Hb and 
Alb. Linear and cubic regression were used to analyze the data. The Kruskal Wallis 
test was used for comparison of groups. A probability value of < .05 was considered 
statistically significant. The percentage of fetuses with an Alb below 2 standard 
deviations (SD) were calculated in each subpopulation to evaluate whether the role 
of hypoalbuminemia in evolving hydrops is more likely to be the primary cause or a 
secondary effect. These percentages were compared in a chi-square (Fisher’s exact) 
test. Ordinal logistic regression was performed to analyze the dependency of the 
decrease in Alb and the decrease in Hb for the presence of hydrops. 
Results
A total of 224 fetuses could be included from which 161 fetuses were nonhydropic, 
44 fetuses were mildly hydropic, and 19 fetuses were severely hydropic. Gestational 
age at the time of the first fetal blood sampling ranged from 17 to 38 weeks. 
Hbs in fetal blood that were plotted against gestational age are shown in Figure 1. 




mean for gestational age (Hb deficit ranged from -1.2 to -11.8 SD). In the nonhydropic 
group, the mean Hb deficit was 7.1 SD (range, -1.2 to -10.5 SD). Mild hydrops was 
observed in fetuses with a mean Hb deficit of 9.2 SD (range, -3.5 to -11.8 SD). Severe 
hydrops was present only in fetuses with a Hb deficit of >9.4 SD. In this group, the 
mean Hb deficit was 10.3 SD (range, -9.4 to -11.4 SD). Mean Hb deficit among the 
3 groups was statistically significantly different (p< 0.001). 
Albs in fetal blood that was plotted against gestational age are shown in Figure 2. In 
the nonhydropic group, the mean Alb deficit was 0.6 SD (95%CI, -0.8 to -0.5; range, 
+2.9 to -3.2 SD). Mildly hydropic fetuses had a mean Alb deficit of 1.1 SD (95%CI, 
-1.3 to -0.8; range, +0.8 to -3.0 SD). Severely hydropic fetuses had a mean Alb deficit 
of 2.1 SD (95%CI, -2.6 to -1.6; range, -0.1 to -4.6 SD). The mean Alb deficit among 
the 3 groups was statistically significantly different (p< 0.001). 
Only 27 of the 244 fetuses were found to have hypoalbuminemia. Of the nonhydropic 
fetuses, 5.6% had an Alb outside the normal range; of the mildly hydropic fetuses, 
13.6% had an Alb outside the normal range, and of the severely hydropic fetuses, 
63.2% had an Alb outside the normal range. Of all hydropic fetuses combined, mild 
and severe together, 28.6% had an Alb <2 SD. The difference in percentage of 
fetuses with hypoalbuminemia between nonhydropic and mildly hydropic fetuses is 
not statistically significant (p= 0.097, Fisher’s exact test). The difference in percentage 
of hypoalbuminemia between severely hydropic fetuses and both nonhydropic and 
mildly hydropic fetuses is statistically significant (p< 0.001 and p< 0.001, chi-square 
and Fisher’s exact test). 
Gestational age independent Z-values of Alb and Hb were compared (Figure 3). A 
cubic regression line fitted the data best for the total population. Ordinal logistic 
regression showed that a decrease in Alb and a decrease in Hb independently of 
each other are predictive of the presence and severity of hydrops (p< 0.001). 
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Figure 1  Hbs in nonhydropic, mildly hydropic, and severely hydropic fetuses are plotted with the normal range 
(* adapted from Nicolaides [14]). 
Figure 2  Albs in nonhydropic, mildly hydropic, and severely hydropic fetuses are plotted with the normal range 





In this study of a large cohort of anemic human fetuses, we found a significant 
negative correlation between the fetal serum Alb and the degree of fetal hydrops. 
However, most of the fetuses with hydrops had albumin levels within the normal 
range. These results suggest that hypoalbuminemia is unlikely to cause the primary 
onset of fetal immune hydrops. This conclusion is supported by the observation that 
there was little difference between nonhydropic and mildly hydropic fetuses. Only 
in severe hydrops was hypoalbuminemia present in more than one half of the cases. 
Hypoalbuminemia thus seems to occur as a secondary effect in the cascade of 
hydrops (eg, because of a reduced re-uptake of albumin from the interstitial 
compartment). Hypoalbuminemia might even be the trigger for mild hydrops to evolve 
into severe hydrops. 
The result of our study also warrants caution in drawing conclusions about the 
relationship between the presence of hydrops and the Alb, because the severity of 
anemia seems to be a confounding factor in this relationship. Hypoalbuminemia was 
observed only in fetuses with an Hb deficit of >8 SDs. Severe anemia could be 
associated, for example, with a relatively large plasma volume, which could cause a 
dilution of plasma proteins. Besides a decrease in Alb, a decrease in Hb was 
independently predictive for the presence of hydrops. Therefore, the development 
Figure 3  Z-albumin plotted against Z-hemoglobin that compares nonhydropic, mildly hydropic, and severely 
hydropic fetuses. The normal ranges that were used to calculate Z-values were adapted from Nicolaides [14] 
and Takagi [15]. 
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of hydrops cannot be explained solely by either the severe anemia or hypoalbuminemia. 
Our data do not permit us to draw conclusions about the reasons that some anemic 
fetuses become hydropic when others remain without hydrops. 
Our study confirms results from animal experiments in which fetal lambs were made 
anemic, with hydrops developing in some lambs and not in others. Both groups of 
fetal lambs were found to have the same level of plasma protein [16]. Our findings 
seem to be in contrast, however, to results from a study by Nicolaides et al. [17]. 
They compared albumin levels from 10 nonhydropic anemic fetuses and 7 hydropic 
anemic fetuses with normal control fetuses. They found that most hydropic fetuses 
(6/7) and only a few nonhydropic fetuses (2/10) had an Alb of <2 SDs. However, from 
a graph in their paper, it appears that, in only 3 hydropic fetuses, the albumin values 
clearly fell below the normal limits. The degree of anemia was the most severe in 
these 3 fetuses. 
This is the first study to explore the possible role of hypoalbuminemia with a large 
number of severely anemic and hydropic fetuses. An obvious limitation is that our 
conclusions are based only on fetuses with alloimmune anemia. Other conditions 
that lead to hydrops may have a different pathophysiologic condition. In some of 
these conditions, hypoalbuminemia may play a more important role. However, many 
other causes of hydrops (such as viral infections, vascular tumors, hematologic 
conditions, and several metabolic conditions) are anemia related and thereby likely 
to have a pathophysiologic condition that is similar to alloimmune hemolytic disease. 
We speculate therefore that, in most nonimmune fetal conditions that lead to hydrops, 
hypoalbuminemia is unlikely to play a causative role. 
In our study, we measured fetal albumin levels and assumed a close correlation with 
intravascular colloid osmotic pressures. Experimental protein reduction in fetal lambs 
was shown to decrease protein levels and colloid osmotic pressures to the same 
extent without causing edema [18]. Lumbers et al. [19] showed, again in fetal lambs, 
a close correlation between plasma protein levels and colloid osmotic pressures. 
In conclusion, hypoalbuminemia was not found in most hydropic anemic fetuses. In 
the chain of events that leads to hydrops, other mechanisms (such as cardiac failure 
and lymphatic flow obstruction) are likely to be more important. In the search for 
better understanding that would lead eventually to effective treatment strategies for 
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Addendum: Letter to the editors 
(of American Journal of Obstetrics and Gynecology)
Alfa-fetoprotein and albumin levels together are more predictive 
of severe fetal hydrops
To the editors
The recent paper by Pasman et al. [1] concludes that “hypoalbuminemia is unlikely 
to cause the initial development of immune hydrops”, yet in severe hydrops, 
hypoalbuminemia was present in more than half the cases. Alfa-fetoprotein, a fetal 
liver product, may be involved in (extramedullary) fetal hematopoiesis and in the 
development of severe allo-immune hydrops [2]. Alfa-fetoprotein levels vary by 
compartment (fetal, placental, maternal), gestational age, and physiologic variables 
[3], so that both low and high maternal serum values have been described as clinically 
important fetal markers [4]. We suggest that concomitant assessment of albumin 
and alfa-fetoprotein may be predictive of severe fetal hydrops (rather than the absolute 
value of fetal albumin or alfa-fetoprotein alone) because together they are reflective 
of the sequence of events in red blood cell allo-immunized pregnancies and fetuses. 
We believe that findings of overt fetal hypoalbuminemia together with elevated fetal 
alfa-fetoprotein may differentiate the fetus with severe hydrops from the fetus whose 
course will be milder. 
Sorina Granovsky-Grisaru, MD
Deborah Elstein, PhD
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We appreciate the interest of Dr Elstein in our work. We apparently succeeded in 
one of our main goals, which was to stimulate discussion and development of new 
hypotheses. Dr Elstein speculates on the possible relation of alpha-fetoprotein (AFP) 
to albumin with the severity of fetal hydrops. She suggests that albumin and AFP 
together are reflective of the sequence of events in red blood cell allo-immunized 
pregnancies. First, one of the important factors, oncotic pressure, is unlikely to be 
influenced significantly by AFP changes, since the concentration of AFP in fetal serum 
is about 10 times lower than albumin concentration, with similar molecular size. Only 
when a large difference in negative charges would be present, which is unlikely to 
be the case in these similar proteins, would a more important contribution of AFP be 
understandable. 
Second, AFP may be a regulating factor in hematopoiesis. Bartha et al. showed that 
AFP in maternal serum correlates with fetal MCA Doppler measurements and 
hemoglobin concentrations [1]. However, in a previous study by the same group, a 
decrease of maternal serum AFP in severely anemic and often hydropic fetuses was 
found [2]. Strikingly, this is very similar to our observation that fetal serum albumin 
concentration was decreased only in severely anemic fetuses that were often, but 
not always, hydropic. It is compelling to hypothesize that the decrease in albumin 
and AFP in severe anemia has a common etiology. Zhang et al. showed that 
hepatoblast cells express both albumin and AFP and seem to facilitate hematopoiesis 
in the human fetal liver [3]. Increased venous pressure and excessive erythropoiesis 
are thought to affect fetal liver function, which could result in decreased AFP and 
albumin production. In turn, these changes could aggrevate anemia and fluid shifts. 
It would be of interest to assess associations between maternal serum AFP, fetal 
albumin concentrations, and severity of fetal anemia and hydrops. Because we 
studied human fetuses during treatment, we were only able to obtain fetal blood 
samples at one moment in time. To provide more insight in the roles of AFP and 
albumin in the development of hydrops, frequent serial blood sampling without giving 
any treatment would be needed. Such an invasive study is obviously not justifiable 
in human pregnancies. 
Suzanne A. Pasman, MD
Frank P.H.A. Vandenbussche, PhD
Dick Oepkes, PhD
Leiden University Medical Center, The Netherlands
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Total blood volume is maintained 
in nonhydropic fetuses 






Fetal alloimmune anemia is associated with increased blood flow velocities and 
cardiomegaly. In severe cases, hydrops can develop. We investigated whether the 
decrease of red blood cell volume is associated with a reduction or expansion of 
plasma volume. 
Methods
In 86 alloimmunized fetuses that received a first intrauterine transfusion, we calculated 
fetal total blood volumes (i.e. fetoplacental blood volumes) using a dilutional principle 
of fetal hemoglobin with adult hemoglobin. The relation between total blood volume 
and estimated fetal weight, severity of anemia and hydrops was analyzed. 
Results
Gestational age ranged from 17 to 35 weeks. Mean hemoglobin deficit was 6.8 
standard deviations (range 2.1–11.7) below the normal mean. Fetal total blood volume 
was significantly related to estimated fetal weight (p< 0.001). Mean total blood 
volume in nonhydropic fetuses was 123 ml/kg (n= 74) and in hydropic fetuses 144 
ml/kg (n= 12). There was a significant relation between total blood volume per kg 
body weight and hydrops (p= 0.035); however, there was no relation with severity 
of anemia (p= 0.94). 
Conclusion
In the human nonhydropic fetus with severe hemolytic anemia, total blood volume 
is maintained: the decrease in red blood cell volume is thus compensated by an 
increase in plasma volume. In hydropic fetuses, however, total blood volume seems 
to be increased. This is in accordance with the hypothesis that congestive heart failure 
plays a role in the pathophysiology of hydrops in anemic fetuses. 
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Introduction
In the human fetus, hemolytic anemia is most frequently caused by maternal allo-
antibodies against fetal red cells. Intrauterine transfusion of red blood cells has 
become an established therapy. Nowadays, the diagnosis of fetal anemia is mainly 
based on ultrasound and Doppler findings, such as cardio-, hepato- and splenomegaly, 
and increased arterial and venous flow velocities. In severe cases, hydrops can be 
observed, usually beginning with discrete ascites and pericardial effusion, followed 
by massive ascites and skin edema in a more advanced stage [1]. 
Fetal total blood volume, also referred to as fetoplacental blood volume, can be 
regarded as the combination of red cell volume and plasma volume, circulating in the 
fetus and the placenta. Theoretically, a considerable decrease of red cell volume may 
be associated with a similar reduction in plasma volume, or a compensatory increase, 
or even an overcompensating expansion in plasma volume. Adults with chronic 
anemia commonly have an increase in plasma volume with a slightly decreased total 
blood volume [2]. In neonates with alloimmune anemia, the decrease in red cell 
volume is mostly found to be compensated by the increase in plasma volume [3,4]. 
In the fetus, however, there are indications that the capillary filtration coefficient and 
vascular compliance are different from that in the neonate or adult [5]. Thus, the fetus 
may react differently compared to neonates or adults. Also, in the severely anemic 
fetus, cardiomegaly, raised umbilical venous flow and hydrops are possible signs of 
congestive heart failure. High-output cardiac failure is thought to play a role in the 
pathophysiology of hydrops. Raised cardiac output indeed has been found in anemic 
fetuses [6–8] and in anemic neonates [9, 10]. In adults, congestive heart failure is 
often associated with increased total blood volume [11]. Therefore, we sought to 
determine whether the loss of red cells is associated with a reduction or expansion 
of total blood volume in the fetus. 
Several methods have been used to estimate fetal total blood volume. Most methods 
used the increase in hematocrit during an intrauterine transfusion to calculate the 
initial total blood volume. However, these methods either overestimated the blood 
volume by assuming that the final blood volume equals the initial blood volume [12], 
or they underestimated the blood volume by assuming that the final blood volume 
equals the sum of the initial blood volume with the added donor blood volume [13–16]. 
In animal experiments, both assumptions were shown to be incorrect, as around 
30% of the volume given during transfusion immediately leaves the circulation [17]. 
Rapid plasma loss during transfusion was also suggested in a study in human fetuses 
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[18]. Hoogeveen et al. [19] therefore proposed another method to estimate fetal total 
blood volume: a calculation based on the dilution of fetal hemoglobin with adult 
(donor) hemoglobin during an intrauterine transfusion. We calculated fetal blood 
volume using this formula, with minor adaptations, and investigated the relation 
between fetal total blood volume and severity of anemia or presence of hydrops. 
Methods 
Measurements and Inclusion Criteria 
Leiden University Medical Center is the national referral centre for the treatment of 
fetal anemia in the Netherlands. Our methods for diagnosis and treatment of severe 
fetal alloimmune anemia with intrauterine transfusion have been described previously 
[20]. In short, a pre-transfusion sample is taken to measure the hemoglobin 
concentration and hematocrit, to determine the required amount of donor blood. 
After the transfusion and a 2-min waiting period to allow even distribution of the 
donor blood, a post-transfusion sample is taken to check if the desired level of 
hematocrit is reached. The hemoglobin concentration and the hematocrit of the fetal 
blood samples are measured using a Sysmex XE 2100 hematology analyzer (Sysmex, 
Kobe, Japan). The hematocrit of the donor blood is determined by capillary high-spin 
centrifugation. Also, fetal total blood volume is routinely calculated at every transfusion. 
In the initial and the final sample, the percentage of fetal hemoglobin is measured 
using high-performance liquid chromatography (HPLC, Primus Ultra 2 ; Siemens, The 
Netherlands). The measurement is the same as for routine HbA1c determination. 
The fetal hemoglobin and the derived (glycated or acetylated) fetal hemoglobin peak 
are combined to determine the total amount of fetal hemoglobin. During the study 
period, from January 2002 to April 2006, we included all first intrauterine transfusions 
for fetal anemia due to red cell allo-immunization. At subsequent transfusions, there 
usually is only a small amount of fetal hemoglobin left, making measurement of the 
dilution of fetal hemoglobin less accurate. 
Estimated fetal weight was determined with the formula of Hadlock et al. [21], using 
sonographically measured biparietal diameter, head circumference, abdominal 
circumference and femur length, within 2 days before or at the time of transfusion. 
Hydropic fetuses were classified as mild or severe using criteria described by van 
Kamp et al. [22]. Briefly, mild hydrops was defined as the presence of a distinct rim 
of ascites, with or without pericardial effusion, while severe hydrops was defined as 
6
91
Fetal total blood volume
the presence of a more abundant amount of fluid collection, usually ascites, with skin 
edema. In severely hydropic fetuses, fetal weight was also estimated using the 
formula of Hadlock et al. [21], but with a measurement of the abdominal circumference 
that excluded the abundant amount of ascites. For this purpose, the tracing elipse, 
in the usual transverse plane, included all fetal organs, except the intra-abdominal 
collection of fluid and the anterior abdominal wall. In this way an attempt was made 
to estimate the nonhydropic size of the fetus. We excluded fetuses with non-immune 
hydrops, structural or chromosomal anomalies or congenital infection. 
Calculations 
The initial total blood volume was calculated with a formula based on the 
dilutional principle as described by Hoogeveen et al. [19]. Basically, with the known 
amount of adult hemoglobin in the donor blood, and the dilution of fetal hemoglobin 
with adult hemoglobin, the initial red cell volume can be calculated (formula 1). The 
assumption herein is that the mean corpuscular hemoglobin concentration (MCHC) 
in the fetal and the donor blood is approximately the same. In that case, the change 
in hemoglobin concentration during transfusion is representative for the change in 
red cell volume during transfusion. 
(1) RCV initial = [ (V donor x Ht donor) x HbF final ] / (HbF initial – HbF final)
RCV initial is the initial red cell volume, V donor is the volume of transfused donor 
blood, Ht donor is the hematocrit of the donor blood and HbF initial and HbF final are 
the pre-transfusion and post-transfusion percentages of fetal hemoglobin. With the 
initial red cell volume and the initial hematocrit (Ht initial), the initial total blood volume 
(FBV initial) can be determined (formula 2). The volume of the initial sample (V sample) 
is taken into account, to determine the entire initial total blood volume. 
(2) FBV initial = [ (V sample x Ht initial) + RCV initial ] / Ht initial
Data Analysis
First, severity of anemia was expressed as the standardized hemoglobin deficit, 
defined as the number of standard deviations that an actual value deviated from the 
normal mean for gestational age. Reference values for hemoglobin were derived 
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from the literature [23]. Then, the variation in MCHC was analyzed and a paired 
samples t test was performed to rule out the possibility of a large difference between 
MCHC before and after transfusion. Further, it was possible to estimate the 
measurement error of our calculation, since in some cases an interim blood sample 
was taken during transfusion. This gave us the opportunity to compare 2 
measurements of total blood volume in the same fetus. These 2 measurements were 
compared in a Bland-Altman plot. Next, linear regression was performed to study the 
relation between estimated fetal weight and fetal total blood volume. The standard 
deviations of fetal total blood volume were given per weight category. Pearson’s 
correlation coefficient was calculated after log transformation of estimated fetal 
weight and total blood volume, since these variables both grow exponentially during 
gestation, to analyze the correlation between estimated fetal weight and total blood 
volume. Then the average fetal total blood volume per kg body weight was determined 
in nonhydropic, mildly hydropic and severely hydropic fetuses. To study the additional 
influence of the severity of anemia and presence and severity of hydrops on fetal 
blood volume, multivariate regression analysis was performed, with fetal blood 
volume per kg body weight as dependent and severity of anemia and hydrops (as an 
ordinal variable) as independent variables. The null hypothesis was that there was 
no significant correlation between fetal total blood volume per kg body weight and 
severity of anemia or hydrops. We considered p< 0.05 to be significant. The statistical 
software SPSS 14.0.1 and Graphpad Prism 5.0 were used. 
Results
From January 2002 to April 2006, we performed 112 first intrauterine transfusions 
in alloimmunized anemic fetuses. We included 86 transfusions with complete data. 
Alloimmunization, at the time of transfusion, was caused by anti-D or anti-D+C (n= 
69), anti-Kell (n= 10), anti-c (n= 4), anti-Jka (n= 1), anti-Kpa (n= 1) and anti-Verdegaal 
(n= 1). Patient baseline characteristics are shown in table 1. Mean hemoglobin deficit 
was 6.8 standard deviations below the normal mean, with a range of –2.1 to –11.7 
standard deviations. 
The mean MCHC before transfusion was 20.4 (n= 85, SD= 1.2), the mean MCHC of 
the donor blood was 20.9 (n= 19, SD= 0.5) and the mean MCHC after transfusion 
was 21.1 (n= 81, SD= 0.8). There was a mean increase of 0.7 in MCHC after 
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In 9 nonhydropic cases an interim blood sample was taken. In these cases the 
measurements of the blood volumes, calculated with the interim and the final blood 
samples, were compared in a Bland-Altman plot. The bias between the 2 methods 
was small: the interim measurement was on average 1.1 ml higher. The SD of the 
differences, however, was 15.8 ml (95% limits of agreement= –32.1 to 29.9 ml; 
percent SD= 10.2%, with 95% limits of agreement= –21.7% to 18.4%). Figure 1 
shows that the average fetal total blood volume had no influence on the extent of 
the difference between the 2 methods. 
Figure 2 shows that there is a strong relation between fetal total blood volume and 
estimated fetal weight, both in nonhydropic and hydropic fetuses. Variance of fetal 
total blood volume increased with increasing estimated fetal weight. Under 1 kg, the 
SD was 30 ml; between 1 and 2 kg, the SD was 53 ml; above 2 kg the SD was 61 
ml. Since estimated fetal weight and fetal blood volume increase exponentially during 
gestation, a log transformation was performed. There was a significant correlation 
between log(estimated fetal weight) and log(total blood volume) (p< 0.001, Pearson 
correlation coefficient= 0.96). 
Figure 3 shows the relation between severity of anemia and fetal blood volume per 
kg body weight. The mildly hydropic fetuses had a Z-hemoglobin of less than –6.2 
SD and the severely hydropic cases of less than –9.8 SD. The average total blood 
volume per kg body weight in nonhydropic fetuses was 123 ml/kg (SD= 23 ml/kg). 
However, in hydropic fetuses the average total blood volume per kg body weight 
was higher: 144 ml/kg (SD= 29 ml/kg) (average in mildly hydropic fetuses 144 ml/kg, 
and in severely hydropic fetuses 142 ml/kg). Multivariate regression analysis showed 
that there was a significant relation between fetal total blood volume per kg body 
weight and the presence of hydrops (p= 0.035, r= 14.6, 95%CI= 1.1–28.1); however, 
there was no relation with severity of anemia (Z-hemoglobin; p= 0.94, r= 0.12, 
95%CI= –3.1 to 3.3). 
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Figure 1  The differences between the interim and final blood volumes are compared with their average in a 
Bland-Altman plot. The bias and 95% limits of agreement are depicted. 
Table 1  Patient baseline characteristics. 
first intrauterine transfusion, initial values (n=86)
Gestational age (weeks) 27.5 (17.1 – 35.4) *
Estimated fetal weight (g) 1272 (167 – 3033) *
Hematocrit 0.19 (0.05 - 0.36) *
Hemoglobin (g/dl) 6.3 (1.8 – 11.8) *
Fetal hemoglobin (%) 91 (81 - 96) *
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Figure 3  Relation between fetal total blood volume per kg body weight (ml/kg) and severity of anemia (Z-
hemoglobin). Z-values (in standard deviations) were calculated with normal values adapted from Nicolaides et al. 
[23]. Nonhydropic, mildly hydropic and severely hydropic cases are depicted. 
Figure 2  Relation between calculated fetal total blood volume (ml) and estimated fetal weight (g). Nonhydropic, 




In this study, we found that the calculated total blood volume was strongly correlated 
with the estimated fetal weight. We found no relation between total blood volume 
and severity of anemia. Therefore, we conclude that, with decreasing red cell volume, 
there is a compensating increase in plasma volume. However, there was on average 
a higher fetal total blood volume per kg body weight in hydropic fetuses. 
Human fetal total blood volume has been estimated, in different studies, to lie 
between 94 and 176 ml/kg. Yao et al. [24] estimated the fetoplacental blood volume, 
using a radioactively labelled albumin dilution method, to be 105 ml/kg in the term 
newborn. This volume was determined from the sum of blood volume in the 
newborn plus the residual volume in the cord and placenta [24]. However, it is 
known that plasma is lost from the fetal circulation during labor, resulting in an 
increase of hematocrit and a lowering of fetal blood volume. The study of 
Yao et al. [24] is the only study that was performed in a non-anemic human 
population. Several investigators have used the change in  hematocrit during 
transfusion to calculate the blood volume in anemic fetuses. In a first formula, the 
assumption was made that the transfusion volume was added to the pre-transfusion 
blood volume and that no volume is lost during transfusion. With this formula, the 
mean fetal blood volume was underestimated and calculated to be between 94 
and 115 ml/kg [13–16]. With a second formula, the assumption was made that the 
blood volume before and after transfusion remained the same [12]. With this 
formula, the mean fetal blood volume was overestimated and calculated to be 176 
ml/kg [19]. Another method was proposed by Hoogeveen et al. [19] to calculate 
total blood volume with the use of a dilutional principle (of fetal hemoglobin with 
adult hemoglobin), so the amount of plasma that is lost during transfusion does not 
influence calculations. With this method, which we also used in this study, a mean 
fetal blood volume of 121 ml/kg was found [19]. 
We believe our method to calculate the fetal blood volume is quite accurate, without 
using artificial red cell labelling. A few assumptions have to be made, however. First, 
we assume that the hemoglobin concentration differences are representational of 
the red cell volume differences. This is only true if there is no free hemoglobin in the 
circulation and if there are no differences in MCHC between fetal and donor blood. 
We tested the variation in MCHC  before and after transfusion and found it to be 
small. Second, we neglected the small amount of fetal hemoglobin that can be found 
in donor blood, because in the study by Hoogeveen et al., fetal hemoglobin in the 
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donor blood was always lower than 1% [19]. Finally, we have to accept that errors 
can occur due to measurement errors of hemoglobin, hematocrit and percentage 
fetal hemoglobin. In 9 cases, an interim blood sample was taken, giving us the 
opportunity to verify the range of error that occurs, when using our method to 
determine the total blood volume. The difference between the interim measurement 
and the final measurement had an SD of 16 ml. When estimating the total blood 
volume per kg body weight, there is also a possible error in the sonographically 
estimated fetal weight. Recent literature showed that, when using the formula of 
Hadlock et al. [21] or closely related formulas, in only 86.5% of the cases, the 
prediction was within 15% of actual birth weight [25]. In case of hydrops fetalis, this 
measurement error may be even larger. With increasing fetal weight, the absolute 
error becomes larger, which might also explain the wider variance of fetal blood 
volume that we observed with increasing fetal weight. 
Our finding that the severity of anemia has no influence on fetal total blood volume 
is in agreement with studies in adults and neonates [2–4]. Studies in human fetuses 
have also concluded that there is no evident relation between blood volume and 
severity of anemia or hydrops [13–16]. However, these studies all used the formula 
that underestimates blood volume and that does not take into account a plasma shift 
during transfusion. Our study is the first study that uses the more  accurate calculation 
method to study the influence of anemia on total blood volume in a large number of 
human fetuses. In our study population, some very severely anemic fetuses were 
included, with a hemoglobin deficit of up to 12 SD below the normal mean, making 
it possible to draw conclusions on the entire scope of severity of anemia. We found 
it remarkable to find that even very young fetuses obviously adequately maintain 
their total blood volume. 
Although there was a significant relation between hydrops and fetal total blood 
volume per kg body weight, the sample size of the hydropic fetuses was small, which 
warrants caution in drawing any conclusions. Hydropic fetuses on average had a 17% 
higher blood volume. This is in accordance with the hypothesis that hydrops is (in 
part) a consequence of congestive heart failure, or a state of high-output failure, with 
a rise in venous return. However, the increase in cardiac output that has been reported 
in anemic fetuses [6–8] does not always coincide with an increase in total blood 
volume, as nonhydropic fetuses apparently maintain their blood volume. This must 
result in a hyperdynamic circulation, where the same blood volume has a shorter 
circulation time. The increase in blood flow velocities  corresponds to this phenomenon. 
The cardiomegaly that is usually observed can be explained by the increased stroke 
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volume, most probably resulting from the decrease in peripheral resistance due to 
the decreased viscosity of the blood and vasodilatation [2, 7, 26, 27]. 
It has been shown that the red cell volume is a  better measure for the severity of 
anemia, or oxygen delivery capacity, in sick  neonates, than hemoglobin concentration 
or hematocrit [28, 29]. Since we found  that the decrease in red cell volume, on 
average, is compensated by an increase in plasma volume, the hemoglobin 
concentration or hematocrit is a  representative measure for the severity of anemia, 
in the alloimmunized fetus. When performing an intrauterine transfusion, the 
hematocrit of the initial blood sample therefore is the best basic assumption on which 
the required amount of donor blood can be calculated. The hematocrit of the final 
blood sample can, however, be lower than what is actually achieved, because in the 
days after transfusion there probably will be a return to the initial total blood volume 
and thus a further increase in hematocrit. 
In conclusion, we found an average fetal total blood volume of 123 ml/kg in 
nonhydropic fetuses and 144 ml/kg in hydropic fetuses. In the human nonhydropic 
fetus, total blood volume is maintained when severe hemolytic anemia develops. 
Thus, the decrease in red blood cell volume is compensated by an increase in plasma 
volume. In hydropic fetuses, however, total blood volume seems to be increased. 
Thus, there is an overcompensating expansion in plasma volume. This is in accordance 
with the hypothesis that congestive heart failure plays a role in the pathophysiology 
of hydrops in anemic fetuses. 
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Fluid shift out of the fetal circulation 






Intrauterine transfusion presents a considerable burden on the fetal circulation by 
increasing volume and pressure. Already during transfusion, a fluid shift out of the 
fetal circulation occurs. Aim of the study was to quantify the intraprocedural fluid 
shift, and the effect of procedural and fetal characteristics on this fluid shift. 
Methods
In 95 alloimmunized pregnancies, we calculated fluid shift at first intrauterine 
transfusions, by determining initial and final blood volumes. We evaluated the 
association of the fluid shift with speed and volume of transfusion, severity of anemia 
and presence of hydrops. 
Results
Of the included fetuses, 11 were mildly hydropic and 4 were severely hydropic. A 
mean fluid shift of 36% of transfused volume was found. Fluid shift related positively 
to transfused volume (p<0.001), and inversely to speed of transfusion (ml/kg/min) 
(p<0.001). The % fluid shift of transfused volume was not related to severity of 
anemia (p=0.55) or hydrops (p=0.66). At low gestational age, fetuses had been 
unintentionally burdened with relative high volume and speed of transfusion.  
Discussion
Around one third of transfused volume is lost from the intravascular compartment 
already during intrauterine transfusion. However, a large variation, only partly explained 
by volume and speed of transfusion was observed. Severity of anemia or hydrops 
played no clear-cut role, therefore, other unknown factors that require further studies 
may explain the variation in fluid shift. The probability that hematocrit will still increase 




Fluid shift during intrauterine transfusion
Introduction
During intrauterine red cell transfusion, a considerable volume of donor blood is 
administered in a short period of time. The transfused volume is up to 20 to 60% of 
initial fetoplacental blood volume, while transfusion-times are merely 10 to 30 
minutes. It has been shown that both arterial and venous blood pressure significantly 
increase after intrauterine transfusion [1-4].
Increase in fetoplacental blood volume after transfusion has been shown to be smaller 
than added donor blood volume [5;6]. Red cells cannot leave the intravascular 
compartment so this volume loss is believed to be the result of a loss of plasma. This 
immediate fluid shift can theoretically take place towards the interstitium of the fetus 
or that of the placenta, the maternal circulation or even towards amniotic fluid, for 
example through blood vessels on the surface of the placenta. 
In animal experiments, Brace et al found that 37% of the transfused volume was 
shifted out of circulation already during the procedure [5]. One hour after transfusion, 
another 20% was lost. In a study in human fetuses, Hoogeveen et al found a similar 
mean fluid shift during transfusion of 31% of transfused volume [6]. 
Improved insight in pathophysiology and fluid dynamics around transfusion is 
important to further reduce fetal mortality and morbidity in these high risk pregnancies. 
Prevention of volume overload and prevention of unphysiological elevation of 
hematocrit in the period following transfusion, can be important steps in improving 
safety and decreasing morbidity as a result of intrauterine transfusion  [7].
Purpose of this research was to investigate to what extent the fluid shift was 
influenced by transfusion rate and fetal condition. We hypothesised that the 
amount of fluid shift would be positively correlated with volume and speed of 
transfusion, and could be associated with severity of anemia and presence or 
absence of fetal hydrops.
Methods
Our methods for treatment of severe fetal alloimmune anemia with intrauterine 
transfusion have been described previously [8]. In short, a pre-transfusion sample is 
taken to measure the hemoglobin concentration and hematocrit (Ht). The required 
amount of donor blood (Vdonor) is determined by the formula proposed by Rodeck et 
al. [9]: Vdonor = FPVinitial * (desired Ht- initial Ht)/ Ht donor blood 
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The initial fetoplacental blood volume (FPVinitial) is based on estimated fetal weight 
and normal values for fetoplacental blood volume as proposed by Nicolaides et al. 
[10]. Usually, Rodeck’s formula underestimates the required donor volume, to reach 
desired hematocrit, since the formula does not take an increase in blood volume 
during transfusion into account. Furthermore, normal values found by Nicolaides were 
somewhat lower then we have calculated [6;11]. Packed red cells, with a hematocrit 
of around 80%, are usually transfused at 5 ml/min, depending on fetal heart rate 
stability. After the transfusion and a two minute waiting period, to allow even 
distribution of the donor blood, a post-transfusion sample is taken to check if the 
desired level of hematocrit (45-50%) is reached. Fetoplacental blood volume is 
routinely calculated at every transfusion. 
During the study period, from January 2002 to September 2006, we included all first 
intrauterine transfusions for fetal anemia due to red cell alloimmunization. We 
excluded fetuses with non-immune hydrops, structural or chromosomal anomalies, 
or congenital infection. Estimated fetal weight was determined with the formula of 
Hadlock et al. [12], using sonographically measured biparietal diameter, head 
circumference, abdominal circumference and femur length, within two days before 
or at the time of transfusion. Hydropic fetuses were classified as mild or severe using 
criteria described by Van Kamp et al. [13]. Briefly, mild hydrops was defined as the 
presence of a distinct rim of ascites, with or without pericardial effusion, while severe 
hydrops was defined as the presence of a more abundant amount of fluid collection, 
usually ascites, with skin edema. In severely hydropic fetuses, fetal weight was also 
estimated using the formula of Hadlock, but with a measurement of the abdominal 
circumference that excluded the abundant amount of ascites. For this purpose, the 
tracing elipse, in the usual transverse plane, included all fetal organs, except the 
intra-abdominal collection of fluid and the anterior abdominal wall. In this way an 
attempt was made to estimate the nonhydropic size of the fetus. 
Initial fetoplacental blood volume (FPVinitial) was calculated as described by our group 
previously [11]. In short, given the known amount of adult hemoglobin in the donor 
blood, and the dilution of fetal hemoglobin with adult hemoglobin, the initial red cell 
volume (RCVinitial) can be calculated. Since the initial hematocrit is known, initial 
fetoplacental blood volume can then be determined. 
The volume (V) and hematocrit (Ht) of the initial sample and the transfused donor 
blood, are used for calculation of final red cell volume (RCVfinal). The final hematocrit 
together with calculated final red cell volume determines final fetoplacental blood 
volume (FPVfinal). Next, the difference between initial blood volume with added donor 
blood volume and the calculated final blood volume, determines the fluid shift. The 
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volume of atracurium (atr) and saline (NaCl) administered during transfusion are taken 
into account, to determine the most exact volume of fluid shift. 
The following formulae where used to determine the final fetoplacental blood volume 
and subsequently the volume of fluid shift:
RCVfinal = RCVinitial – (Vsample*Htinitial) + (Vdonor*Htdonor)
FPVfinal = RCVfinal / Htfinal
Vfluid shift = FPVinitial – Vsample + Vatr + Vdonor + VNaCl – FPVfinal 
To calculate transfusion speed, the time at first sampling and at last sampling was 
noted. Thus, time during occasional needle dislodgement or complications otherwise 
delaying the procedure was included. 
Linear regression analysis was used to investigate the relations between fluid shift 
and transfused volume, and speed of transfusion. Quadratic regression analysis was 
used to investigate the relation between speed of transfusion and gestational age. 
Severity of anemia was expressed as the standardized hemoglobin deficit 
(Z-hemoglobin), defined as the number of standard deviations that an actual value 
deviated from the normal mean for gestational age. Reference values for hemoglobin 
were derived from the literature [14]. Linear regression analysis was used to investigate 
the relation between the percentage of fluid shift of transfused volume and severity 
of anemia (Z-hemoglobin). Oneway anova was used to test the difference between 
the percentage of fluid shift of transfused volume in nonhydropic, mildly hydropic and 
severely hydropic fetuses. We considered a p-value of <0.05 to be significant. Statistical 
software programs SPSS 16.0.2 and Graphpad Prism 5.0 were used. 
 
Results
During the study period, we performed 125 first intrauterine transfusions in red cell 
alloimmunized anemic fetuses. We included 95 transfusions with complete data. 
Alloimmunization, was caused by anti-D or anti-D+C (n=74), anti-Kell (n=12), anti-c 
(n=6), anti-Jka (n=1), anti-Kpa (n=1) and anti-Verdegaal (n=1). Gestational age ranged 
from 17 to 35 weeks and estimated fetal weight ranged from 167 to 3033 gr. There 
were 80 nonhydropic fetuses, 11 mildly hydropic and 4 severely hydropic fetuses 
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included. Hemoglobin concentration ranged from 1.8 tot 11.8 g/dl. The severity of 
anemia (Z-hemoglobin) ranged from -2.1 to -11.7 SD and was not related to 
gestational age (p=0.27). 
The mean amount of transfused volume was 52 ml/kg estimated fetal weight. The 
mean amount of transfused volume was 43% of initial fetoplacental blood volume 
and this percentage was strongly correlated to gestational age (p<0.001). Notably, 
fetuses below 20 weeks gestation (with a mean Z-hemoglobin -7.5 SD) received a 
transfused volume of 48 to 99% of initial fetoplacental blood volume, while this was 
11 to 55% in fetuses above 30 weeks gestation (with a mean Z-hemoglobin -6.7 SD).
A fluid shift with a range of 1 to 83 ml was found. The mean fluid shift was 14% of 
the initial fetoplacental blood volume (SE=0.7%, SD=7%) and 36% of the transfused 
volume (SE=2.2%, SD=21%). Figure 1 shows that the fluid shift was positively and 
linearly related to the amount of transfused volume (R2=0.40, p<0.001). 
As shown in figure 2, the fluid shift was inversely related to the speed of transfusion, 
expressed as transfused volume/ estimated fetal weight/ minute (R2=0.18, p<0.001). 
However, there is no evident relation with amount of fluid shift at low transfusion 
speed. Surprisingly, as shown in figure 3, we found a strong decrease of relative 
transfusion speed with gestational age (R2 quadratic=0.68, p<0.001). 
Figure 4 shows the wide variation in fluid shift, without an evident influence of 
severity of anemia or the presence of hydrops. The relation between the percentage 
fluid shift of transfused volume and Z-hemoglobin was not significant (R2=0.01, 
p=0.55). Finally, there was no significant difference, between the means of the 
nonhydropic, the mildly hydropic and the severely hydropic fetuses, in the percentage 
fluid shift of transfused volume (respectively 35%, 41% and 40%, p=0.66). 
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Figure 2  Correlation between transfusion speed and extravascular fluid shift during intrauterine transfusion. 
Hydropic fetuses are depicted.
Figure 1  Correlation between transfused volume and extravascular fluid shift during intrauterine transfusion. 
Hydropic fetuses are depicted.
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Figure 4  Correlation between severity of anemia (Z-hemoglobin) and % fluid shift of transfused volume during 
intrauterine transfusion. Hydropic fetuses are depicted.
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Discussion
In this study, the volume of donor blood given to the fetus was approximately half 
of the initial fetoplacental bloodvolume. The mean extravascular fluid shift during 
intrauterine transfusion was 36% of the transfused volume. As expected, we found 
a positive linear relation between volume of fluid shift and transfused volume. In 
contrast to our hypothesis, the fluid shift was decreased at relatively high speed of 
transfusion. Also, we found no relation between severity of anemia or presence of 
hydrops, and the relative amount of fluid shift.  
Our large human study confirms data from previous animal and human studies, 
showing that around one third of transfused volume leaves the intravascular space 
during transfusion [5;6]. A large interindividual variation was observed, though. This 
may in part be due to measurement error, since some of the measured values (that 
are expected to contain small errors) appear more than once in our formula, enlarging 
the over-all error in calculated fluid shift. Furthermore, biological variation in vascular 
compliance, interstitial compliance and capillary filtration coefficient may explain the 
variation in fluid movement between vascular and interstitial space. In general, the 
fetus is able to keep its blood volume closer to normal than adults after reduction or 
expansion in volume [15;16]. Besides these causes of variation, other factors may 
influence the amount of fluid shift, some of which were investigated by us.
One of the factors influencing fluid shift was the speed of transfusion. We initially 
hypothesised that with increasing speed of transfusion, blood pressure is increased 
accordingly, thus enhancing fluid shift. However, there was a decrease in amount of 
fluid shift with higher transfusion speed. It is possible that vascular compliance 
increases with higher infusion pressure, or capillary filtration capacity restricts fluid 
shift velocity. Apparently fluid shift is a process requiring a certain amount of time. 
It is therefore likely that this process continues after transfusion.   
Other factors, hypothesized to influence the amount of fluid shift, were severity of 
anemia and presence of hydrops. On average, fetuses with severe anemia have a 
decreased concentration of plasma albumin [17]. This may be the result of decreased 
synthesis in the fetal liver  [18] or a relative increase in plasma volume [11]. Another 
possibility is that albumin is lost from the intravascular compartment due to endothelial 
damage [19;20], which could imply an increase in the capillary filtration coefficient. 
Furthermore, a smaller difference between the concentration of albumin in the 
intravascular compartment and the interstitial compartment results in a diminished 
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capacity to contain water in the vascular compartment. Cardiac backward failure, 
leading to an increase in central venous pressure, also could promote extravascular 
fluid shift. Moreover, fetuses are particularly susceptible to interstitial fluid 
accumulation because of their vulnerability to venous pressure on lymphatic return 
[21]. On the other hand, cardiac forward failure could result in a failure to increase 
arterial blood pressure during transfusion, thus relatively reducing fluid shift. Finally, 
congestion in anemia can also be the effect, not of myocardial failure, but of retention 
of fluid in the vascular compartment as a result of a kidney mediated neuro-humoral 
cascade, induced by a low arterial pressure as a consequence of the low hemoglobin 
level [22-24]. In our study, there was no evident difference in fluid shift between 
mildly and severely anemic fetuses and nonhydropic or severely hydropic fetuses. 
Caution in drawing conclusions should be made, since the number of severely 
hydropic fetuses was limited. Our findings, however, are in accordance with the 
findings by Brace et al. [5] and Hoogeveen et al. [6]. Both positive and negative 
influencing factors might be present, thus not resulting in a clear-cut effect on fluid 
shift.
We found that younger fetuses in our hospital were transfused with significantly 
higher relative volumes and speeds. In fact, fetuses below 20 weeks’ gestation were 
transfused with relative speeds up to 5 times higher than fetuses above 32 weeks. 
This usually was an unintentional effect. With increasing gestational age, fetoplacental 
blood volume increases exponentially, since it is linearly correlated with fetal weight 
[11]. A much smaller amount of donor blood is thus required to achieve a desired rise 
in hematocrit in younger fetuses. Further, administering donor blood at the same 
speed is thus a much higher burden in younger fetuses. It is possible that this 
attributed to the fact that low gestational age is a risk factor for complication of 
intrauterine transfusion, besides the increased procedural difficulty [7]. Perinatal 
mortality was 5.6% per procedure between 16 and 20 weeks, compared to 0.8% 
between 32 en 36 weeks. Fetal mortality after intrauterine transfusion has already 
been shown to be associated with a large increase in venous pressure [2], as well 
as with a relative large increase in hematocrit [25].  
In animal experiments, fetal hematocrit was further increased in 1 hour after 
transfusion [5]. Although fetoplacental blood volume was not normalized after 24 
hours, it was found that human fetuses maintain their total blood volume at different 
degrees of anemia [11]. Thus, it can be expected that a return to initial fetoplacental 
blood volume will take place shortly. This has clinical implications, since it may be 
hazardous to let the hematocrit increase to polycythemic values. In a recent (possibly 
pre-selected) cohort of neonates that had received an intrauterine transfusion, 24% 
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showed moderate to severe abnormalities on cranial ultrasound (personal 
communication G. van Wezel-Meijler), possibly baring clinical consequences. This 
may be due not only to hypoxic but also to polycythemic mediated damage. 
The hematocrit in the final sample after transfusion could be considered to be a 
temporary value. The formula of Rodeck [9], that seems to underestimate the required 
amount of donor blood, therefore could actually be a correct guideline, assuming that 
in the hours or days after transfusion fetoplacental blood volume returns to the initial 
value. Final hematocrit in the Rodeck formula would then become the desired level 
that is chosen, not directly after transfusion but after a few hours or days.
The decay of donor cells has been calculated to be around 2% per day  [26], by 
comparing the final hemoglobin level after transfusion with the initial hemoglobin level 
at the subsequent transfusion. This probably is an underestimation of the adult red 
cell decay, assuming that hematocrit first rises in the period after transfusion, before 
it declines again. This problem was already addressed by Egberts et al. since they 
sometimes found a surprisingly low decline and even an increase of adult hemoglobin 
concentration at the second transfusion. Furthermore, it is likely that the donor red 
cells do not decline linearly in time  [27-29]. The difference between the adult red cell 
volumes at the end of transfusions, as calculated in this study, and the adult red cell 
volumes at the beginning of the subsequent transfusions, measured at different time 
intervals, might learn us about the actual decay of donor red cells in human fetuses. 
 
Future research could resolve what other factors influence the fetal cardiovascular 
reaction to intrauterine transfusion. Calculations as were performed in this study can 
be combined with measurements of blood pressure, colloid osmotic pressure or 
rheological measurements before and after transfusion, difference in placenta size, 
changes in ANF, angiotensin, AVP and other hormone concentrations and functional 
echocardiography. From the factors studied in this investigation, volume overload 
can not be easily predicted. Our advice is to be cautious with amount and speed of 
transfusion in younger fetuses and to strive for a hematocrit that is not higher than 
the desired level at the end of transfusion.
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Insights in fetal (patho-)physiology:
old, current and acquired knowledge
 
Around the year 1650, the renowned professor Sylvius taught his medical students 
at the University of Leiden about the fetal circulation [1]. He described a continuous 
circulation of blood that flowed from the mother, through the placenta where it was 
somehow transformed, to the fetus and vice versa. The beating of the fetal heart 
had no function other than ad solam propriam vitam conservadam, or “just to be 
alive”. This of course is the fetal physiological equivalent of a flat world model. We 
have since learned that the fetus has its own circulation, pumping its blood through 
its body, through the umbilical cord and the placenta and back. A layer of chorionic 
cells surrounds the entire fetal compartment: the syncytiotrofoblast is the fetal border 
of the placenta; the chorionic membrane encloses the amniotic fluid compartment 
in which the fetus moves and develops. All exchange of substances between mother 
and fetus takes place through this chorionic layer of cells. The type of cells and the 
specific architecture of the placenta are unique to the human species. Therefore, 
human fetal physiology differs from that of other mammals. 
Also, the fetus is not merely an unborn baby. The fetus and neonate differ in several 
aspects. First, a substantial part of the fetal circulation is extracorporal (in the umbilical 
cord and placenta). Further, since breathing is not yet required to obtain oxygen from 
the air, the lung circulation is only a fraction of what it will be after birth due to a much 
higher pulmonary vascular resistance [2]. Before birth two shortcuts exist to by-pass 
the lung circulation [3]. A great part of the blood that enters the right half of the heart, 
immediately flows to the left side of the heart or to the aorta and thus to the head 
and body instead of the lungs. The first shortcut is the foramen ovale between the 
atria; the second shortcut is the ductus arteriosus between the pulmonary artery and 
the aorta. Finally, there is an intricate system, the ductus venosus, which regulates 
the amount of flow coming from the placenta to either go directly to the right atrium, 
or first to flow through the liver [3]. This system divides the oxygen and nutrient rich 
blood from the placenta over the fetal brain and the fetal liver.
Physiology research in fetal lambs has shown that fetuses are different from neonates 
in other aspects as well. The compliance of the fetal circulation seems higher than 
that of neonates [4]. The compliance of the interstitial space is also higher and is 
therefore more prone to expansion [5]. The lymphatic return is much more vulnerable 
to a rise in venous pressure [6] and the capillary permeability is higher in fetuses 
compared to neonates [7]. It is unknown whether all these effects gradually change 




In this thesis we studied fetal pathophysiology in hemolytic anemia and hydrops, 
with a focus on fluid and protein dynamics. Our studies have led to acquired insights 
in the following aspects: 
First, we studied bilirubin clearance in the fetus. Where hemolytic anemia in neonates 
is frequently accompanied by hyperbilirubinemia, potentially leading to kernicterus, 
fetuses are not known to develop this problem. (Free) bilirubin concentrations in 
fetuses never reach the dangerous levels as they occur in neonates with hemolytic 
anemia. This is due to an (in part active) transport of unconjugated bilirubin over the 
placenta towards the mother [8]. Before bilirubin is transferred over the placenta 
though, it seems to exchange between the fetal blood and the amniotic fluid (chapter 
2 and 3). Unconjugated bilirubin is almost completely bound to albumin in extracellular 
fluids [9]. The bilirubin content in the entire fetal compartment is thus determined 
not only by formation and clearance of bilirubin from the fetal blood, but also by the 
total binding capacity of albumin in the different fetal compartments. Literature review 
showed that amniotic fluid albumin is likely to be of maternal or membrane origin 
instead of fetal origin (chapter 4), thus delineating the hypothesis that bilirubin 
exchanges over the intramembraneous pathway, releasing and binding to albumin 
on either side of the membrane.
Second, we studied the available evidence in the literature on the origin and function 
of albumin in amniotic fluid. We considered all transport mechanisms from the 
amniotic cavity to and from the fetus and the mother. Based on the literature, we 
think that it is very likely that the transport of nutrients not only takes place through 
the placenta, but also in part through the fetal membranes (chapter 4). The amniotic 
fluid might therefore be considered the first enteral nourishment. Fetuses and 
neonates are in this aspect not that different, having a combined enteral intake of 
water and nutrients. A fetus, however, probably drinks much larger amounts daily to 
maintain the recycling process of water in the amniotic cavity [10]. Another option is 
to consider the amniotic cavity to be an extracorporal part of the extravasal 
compartment of the fetus. There seems to be an extensive exchange between the 
amniotic fluid and the fetal blood through the intramembraneous pathway. In other 
words, this compartment is comparable to the interstitial space inside the body of 
the fetus. The difference is that it is not only in contact with the fetal blood, but it is 
also in contact with the mother. The fetal membranes therefore seem to play a crucial 




Third, we studied the difference between hydropic and nonhydropic fetuses. We 
found a different bilirubin to albumin ratio in hydropic fetuses (addenda chapter 2 and 
3), suggesting a difference in albumin binding capacity both in fetal blood and in 
amniotic fluid. This might be explained by competitive binding of an unknown ligand, 
by a change in characteristics for example of pH, or by posttranslational changes in 
albumin, for example an increase in ischemia-modified albumin. Further, we found 
hypoalbuminemia to be more often present in hydropic or severely anemic fetuses 
compared to mildly anemic fetuses (chapter 5). This might be the effect of a decrease 
in albumin production due to excessive hematopoiesis in the fetal liver. The 
hypoalbuminemia could also be the effect of an increase in plasma volume, as we 
found in anemic fetuses (chapter 6). With increasing severity of anemia, thus a 
reduced number of red blood cells, the compensating amount of plasma could cause 
a dilution of the amount of albumin present in the circulation. An overcompensating 
plasma volume in hydropic fetuses (chapter 6) would be in agreement with a further 
decrease in albumin concentration. Finally, hypoalbuminemia could be the effect of 
capillary leakage, caused by hypoxia-related endothelial damage. This might explain 
the rise in protein concentration in amniotic fluid that has been reported in severely 
anemic and hydropic fetuses, possibly due to leakage through the intramembraneous 
pathway. However, when studying the shift of fluid out of the fetal circulation during 
an intrauterine blood transfusion, we did not find any difference between hydropic 
and nonhydropic fetuses (chapter 7). We expected that an altered capillary permeability 
would have influenced the amount of fluid shift that takes place. Multiple contradicting 
effects might on the other hand be present in severe anemia and hydrops, thus 
explaining the indistinct effect on fluid shift. 
Generalized hydrops is a phenomenon rarely seen in adults. An interesting similarity 
of fetal hydrops exists with the, evenly poorly understood symptoms of pre-eclampsia. 
Generalized hydrops is also rarely seen in children or neonates. Part of the explanation 
probably lies in the aforementioned differences in physiology between fetuses and 
neonates. In contrast to neonates and adults, fetuses have greater endurance in 
withstanding the deleterious effects of the causes leading to generalized hydrops, 
without intensive care. As long as fetuses are supplied with a certain amount of 
oxygen, water and nutrients through the placenta and the amniotic fluid, the womb 
can actually be considered to be a “prenatal intensive care unit”. 
Fourth, we studied fetoplacental blood volumes. The average fetoplacental blood 
volume was about 120 ml/kg (chapter 6). The average neonatal blood volume is 
about 90 ml/kg [11]. This implies that about a quarter of the fetoplacental blood 




might vary, especially during blood transfusion. It has been suggested that fetuses 
can tolerate higher volumes and speed of transfusion compared to neonates 
because the placenta can function as an expanding reservoir. Further, we found 
that in severe chronic anemia, fetuses maintain their total blood volume, thus 
compensating the loss of red cells with an increase in plasma volume (chapter 6). 
This seems to be similar to neonates with hemolytic anemia [12;13]. In adults with 
chronic anemia, total blood volume has also been reported to be maintained or to 
be somewhat decreased [14]. In adults, the kidneys function as regulator of both 
red cell volume and total blood volume and thus of hematocrit [15]. Our study 
suggests this regulatory function to be active already from an early gestational age 
onward. 
The acquired insights on the diagnosis, the pathophysiology and the reaction to 
treatment in severe anemic or hydropic fetuses led to several implications for current 





Implications for current practice 
We investigated some of the pathophysiological processes that occur in hemolytic 
anemia and immune hydrops fetalis. This resulted in the following recommendations 
for clinical practice:
1) Bilirubin concentration in amniotic fluid is determined by both the formation of 
bilirubin in fetal blood, and the amount and binding capacity of albumin in the fetus 
and in the amniotic fluid (chapter 2 and 3). The formation of bilirubin is increased during 
hemolysis. The clearance of bilirubin that is formed in the fetus depends on the 
transport over the placenta towards the mother. For many years, prediction of fetal 
hemolytic anemia was performed by measuring the amount of bilirubin in amniotic 
fluid. The Queenan and Liley chart show the cut-off values for the concentration of 
bilirubin in amniotic fluid that indicate the presence of severe hemolytic anemia [16]. 
While working on the studies presented in this thesis, we realized that, since most 
of the bilirubin is bound to albumin, the slope in both the original non-extended Liley 
chart and in the Queenan chart follows that of the average albumin concentration in 
amniotic fluid during gestation. This is illustrated in figure 1 and 2.




We advise to use the Queenan chart instead of the linearly extended Liley chart, 
for prediction of fetal anemia below 24 weeks’ gestation, since the Queenan chart 
better corresponds with the average albumin concentration in this time period. 
2) There are several conditions in which amniotic fluid albumin concentration can 
deviate from the normal average, for example intrauterine growth restriction, 
polyhydramnios or renal abnormalities. In these cases, it therefore must be anticipated 
that bilirubin concentration in amniotic fluid will change accordingly. Also, hydrops is 
associated with a shift in albumin concentration, both in fetal blood (chapter 5), and 
in amniotic fluid [17]. Bilirubin concentration in fetal blood is lower in hydropic fetuses 
compared to nonhydropic severely anemic fetuses (chapter 2). But, because of the 
relatively increased binding capacity in amniotic fluid (chapter 3), the concentration 
of bilirubin in amniotic fluid will still be high in hydropic fetuses. This actually increases 
the clinical usefulness of the Queenan and Liley chart, although in the last decades, 
the use of ultrasound to detect fetal hydrops reduced the need for amniocentesis 
and bilirubin measurement in the severely affected group. 
We advise to beware of differences in the amniotic fluid albumin concentration 
or its binding capacity for bilirubin, that might occur in several pathological 
situations. This influences the bilirubin concentration in amniotic fluid, and 
thus its predictive value for fetal anemia.   
Figure 2  Albumin concentration in amniotic fluid during gestation
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3) Fetal bilirubin spreads through all fetal compartments including the amniotic fluid 
(chapter 3), before it is transported towards the maternal blood. Bilirubin most likely 
enters the amniotic fluid through the intramembraneous pathway, then binding to 
the albumin that is present there. Albumin in amniotic fluid seems to be mostly of 
maternal origin (chapter 4). Thus, the bilirubin-albumin complex detaches and the 
free bilirubin crosses the membrane, after which it attaches again to form a new 
bilirubin-albumin complex. This process takes place from fetal blood towards the 
amniotic fluid, towards the maternal blood and most likely also towards the 
extravascular compartment in the fetus. After birth, bilirubin is being cleared from 
the neonatal blood after the commencing of the conjugation and excretion process 
and after intestinal re-uptake is lowered [18;19]. Then the bilirubin content that is built 
up in the interstitium is recruited into the blood stream. Thus, forementioned process 
reverses, from the extravascular compartment towards the fetal blood. Clinicians need 
to be aware this phenomenon can occur, also after an exchange transfusion, in 
neonates that have had a potentially large accumulation of bilirubin before birth.
We advise to take the possible prenatal accumulation of bilirubin in the 
extravascular compartment into account, that can cause subsequent 
hyperbilirubinemia after birth.   
4) In the past, two different assumptions have been made for the calculation of the 
fetoplacental blood volume. First assumption was that the blood volume before 
transfusion equals that after transfusion [20]. Second assumption was that the blood 
volume after transfusion increases by the amount of donor blood volume that is 
administered during transfusion [21]. Both assumptions do not seem to represent 
reality. During transfusion, part of the plasma immediately leaves the circulation, on 
average about a third of the transfused volume (chapter 7). Further, we found that 
the fetoplacental blood volume, measured before transfusion, was maintained in 
nonhydropic fetuses. Thus, the decrease in red cell volume, due to hemolysis, is 
compensated by an increase in plasma volume. In hydropic fetuses there even seems 
to be an overcompensation of plasma volume (chapter 6). These findings make it 
very likely that after transfusion the fetoplacental blood volume will also normalize 
rapidly. Thus, the other two thirds of the transfused volume probably leave the 
circulation after transfusion, i.e. further reducing the amount of plasma volume. 
Therefore, an increase in hematocrit should be expected to still take place shortly 
after an intrauterine blood transfusion.    
For the calculation of the donor volume that has to be given at an intrauterine 




desired hematocrit of 50% at the end of the transfusion. Thus, a final sample is taken 
to check if the desired level is achieved and blood is transfused until this is corrected. 
The Rodeck formula, however, does not take a fluid shift during transfusion into 
account. Moreover, it should be realized that the hematocrit at the end of transfusion 
is probably not the final hematocrit, because fluid will continue to shift in the hours 
or days after transfusion. It is possible that hazardous levels of hematocrit are 
reached with potential adverse effects. In a recent (possibly pre-selected) cohort 
of neonates that had received an intrauterine transfusion, 24% showed moderate 
to severe abnormalities on cranial ultrasound (personal communication G. van 
Wezel-Meijler), which may be due to hypoxia but also to polycythemia mediated 
damage. Because the Rodeck formula does not take a change in blood volume into 
account, it actually is a useful formula, assuming that blood volume returns to 
normal shortly after transfusion. It might be acceptable to aim for a hematocrit of 
55% in nonhydropic fetuses [22], when striving for a maximal prolongation of time 
until delivery or next transfusion. However, it should not be expected to be reached 
at the end of transfusion and the calculated amount of donor blood should not be 
exceeded. When choosing the desired level of hematocrit, the risk of brain damage 
mediated by polycytemia has to be weighed against the risk of an additional 
intrauterine intervention [23]. Finally, estimated blood volumes as reported  in 
chapter 6 can be used for the calculation of the donor volume. 
We advise to use the Rodeck formula to calculate the volume of donor blood 
that has to be given during transfusion. The hematocrit is expected to still 
increase after transfusion and should thus not be expected to already be at the 
desired level at the end of transfusion.
5) A relative high transfusion speed probably lowers the amount of fluid shift during 
intrauterine blood transfusion (chapter 7). This would imply that in case of high 
transfusion speed, the measured final hematocrit is even less predictive since the 
hematocrit will increase even more after transfusion. In our study period, we found 
that in younger fetuses, relative volume and speed of transfusion was many times 
higher than in older fetuses. Since fetoplacental blood volume increases exponentially 
during gestation (figure 3), volume and pressure burden will be many times higher if 
transfusion policy is not adjusted at lower gestational ages. Advisable is, since donor 
blood is administered at 5 ml/min in 30 to 35 weeks old fetuses, transfusion speed 
should be lowered to 4 ml/min in 25 to 30 weeks, to 3 ml/min at 20 to 25 weeks, 
and to 2 ml/min or less below 20 weeks gestation (table 1). In addition, desired 
hematocrit or desired hemoglobin level should be adjusted to normal values for 
gestational age [24]. 
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We advise to adjust the transfusion speed and the donor volume administered 
during intrauterine transfusion, according to the gestational age or estimated 
fetal weight of the fetus.
6) In case of hydrops, extra care should be taken to avoid volume or pressure 
overload, thus even lower speed of transfusion is advisable. Even though no obvious 
relation was present between fluid shift and severity of anemia or presence of 
hydrops (chapter 7), based on the literature (and clinical experience) it seems 
Tabel 1  Volume burden expressed as percentage of transfused volume/ fetoplacental blood volume (FPV)/ 
min, when using the standard 5 ml/min or the proposed transfusion speeds at different gestational ages.  
Weeks EFW* FPV** ml/min %FPV/min ml/min % FPV/min
15 120 15 5 33,3% 1 6,7%
20 330 41 5 12,2% 2 4,9%
25 790 97 5 5,1% 3 3,1%
30 1550 190 5 2,6% 4 2,1%
35 2600 320 5 1,6% 5 1,6%
* EFW: fetal weight in g.  [25], ** FPV 123 ml/kg (chapter 6)
Figure 3 Fetoplacental blood volume in relation with gestational age, with the quadratic regression line shown 




hazardous to achieve a large difference in hematocrit in a short period of time [26;27]. 
Thus, in hydropic or severely anemic fetuses we prefer to aim for a lower final 
hematocrit e.g. 30%. Exchange transfusion or intraperitoneal addition of transfusion 
are other options to avoid direct volume and pressure overload. Finally, the relative 
increase in total blood volume in hydropic fetuses (chapter 6) may normalize with 
improvement of fetal condition, thus still somewhat increasing hematocrit.
We advise that severely anemic and hydropic fetuses should only be burdened 




Implications for future research
The results from the studies performed in this thesis provide further insight in the 
pathophysiology of alloimmune anemia, bringing forth new questions to be researched. 
These questions can also be extended to the field of other fetal diseases and in 
general to fetal physiology. These questions can be translated to the following 
propositions for future research.    
1) The large interindividual variation in albumin concentration in amniotic fluid can 
hamper the sensitivity of the Queenan or extended Liley chart. The accuracy for the 
prediction of fetal anemia by measuring the amniotic fluid bilirubin to albumin ratio 
(or BAR), that avoids this problem, could be investigated prospectively. Maternal 
obesity, unusual position of the fetus or concomitant pathology can make prediction 
of fetal anemia with ultrasound difficult. Especially below 18 weeks gestation the 
measurement of the peak systolic velocity in the middle cerebral artery may become 
less accurate or more difficult to obtain. The presently used Liley chart is also not 
accurate in this time period. Furthermore, the risk of intrauterine transfusion is 
significantly increased below 20 weeks gestation [23]. Thus, performing an 
amniocentesis to measure the bilirubin to albumin ratio, to aid in the diagnosis of 
fetal anemia, may be worthwhile especially at low gestational age. Postnatally, the 
bilirubin to albumin ratio is already being investigated in a multicenter trial (BARtrial), 
to see whether this ratio is a valuable addition to total serum bilirubin concentration, 
when used as phototherapy and exchange transfusion cut-off value, for the prevention 
of neurological sequelae [28]. It would be of interest to also investigate the albumin 
binding capacity for bilirubin in hydropic and nonhydropic fetuses and to compare 
prenatal with postnatal binding capacity [28;29]. A lowered reserve binding capacity 
could imply an increased risk of free bilirubin toxicity [30].  
Studies on pre- as well as post-natal measurements of the bilirubin to albumin 
ratio may improve the treatment of fetuses and neonates with blood group 
immunization problems. 
2) Review of the available evidence on the origin of amniotic fluid albumin showed that 
there are many questions left unanswered since the 1970s (chapter 4). Studies on the 
origin of albumin and on the transport mechanism through the so-called intra- and 
transmembraneous pathways are of great interest. Using albumin as a study object, it 
may become possible to gain more knowledge on the homeostasis of amniotic fluid 
volume and composition. The intramembraneous pathway is thought to play a crucial 




many fetal diseases and may pose obstetrical problems. Many in vitro studies (as 
proposed in chapter 4) using human placenta and membranes can be designed.
Studies on the origin of albumin and on the transport mechanism through the 
fetal membranes will increase our knowledge, among others, of amniotic fluid 
homeostasis. 
3) Since albumin in amniotic fluid is probably mostly of maternal origin, the possibility 
of transamniotic fetal nutrition becomes of interest. Especially since albumin is a 
carrier protein among others for fatty acids and minerals. Intrauterine growth 
restriction as a result of placental insufficiency is an important obstetric problem. 
Although the diminished supply of nutrients is not the only problem of placental 
insufficiency since it may be accompanied by problems in oxygenation, an increase 
in prenatal nourishment might improve outcome. Studies on transamniotic feeding 
in animal studies have so far given paradoxical and disappointing results [31-33]. 
However, understanding of the physiological role of transamniotic feeding might be 
the key to designing a fetal therapy for intrauterine growth restriction.
Studies on physiological transamniotic feeding can give directions for the 
research on the development of fetal therapy for intrauterine growth 
restriction.     
4) Hypoalbuminemia seems to be a secondary effect of hydrops (chapter 5) and may 
in part be due to an increase in plasma volume (chapter 6). It would be of interest to 
investigate the albumin concentration in different fetal compartments as ascites and 
hydrothorax and compare this with values in amniotic fluid and fetal blood, to gain 
insight in the amount of albumin that builds up in these different compartments in 
hydrops. Besides, many other questions on fetal pathophysiology are still unanswered. 
Research developed using animal or computer models will give rise to hypotheses that 
have to be verified in human studies. In this thesis, the collection of simultaneous fetal 
blood and amniotic fluid samples was essential to test our hypothesis (chapter 3). 
We therefore want to advocate the prospective collection of scarce and unique human 
fetal samples, that are otherwise discarded. It would be most valuable to collect and 
store samples of different fetal compartments, that have been taken simultaneously. 
Preferably a perinatal biobanking should be achieved of pre- and postnatally collected 
samples, for example of ascites or pleural effusion, in combination with fetal (cord) 
blood and/or maternal blood and/or amniotic fluid. 
Collection of samples simultaneously obtained in different fetal compartments 
will be very valuable for perinatal pathophysiology research. 
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5) Cardiovascular changes play a crucial part in hydrops fetalis. The question remains 
whether there is an actual myocardial failure in anemia induced hydrops, or if the 
cardiovascular changes are an effect of the hyperdynamic circulation or in other 
words, represent a high output state. The low concentration of hemoglobin causes 
a low arterial pressure due to a decrease in viscosity and possibly due the periferal 
vasodilatation. Vasodilatation may be mediated for example by endothelium-derived 
relaxing factor, which is regulated by hemoglobin concentration [34]. The kidneys 
may mediate a neurohumoral cascade that increases plasma volume, as to rise cardiac 
filling pressure and increase cardiac output, thus maintaining arterial pressure [35]. 
This cascade eventually might lead to overcompensation of plasma retention and a 
rise in venous pressure, thus causing the development of hydrops fetalis. It would 
be of interest to differentiate between actual myocardial failure and a state of high 
output congestion with a cardiac function that can quickly return to normal when the 
underlying condition is treated. Actual myocardial failure might be present for example 
in recipient twins in severe TTS, or in fetuses effected by Parvovirus B19 with a 
cardiomyopathy. High output cardiac failure may be present for example in twin 
arterial perfusion syndrome, or in fetuses with sacrococcygeal teratoma or placental 
chorioangioma. Studies (as proposed in chapter 7) on the difference between hydropic 
and nonhydropic fetuses could eventually give insight in the pathophysiology of fetal 
high output cardiac failure.  
Studies on the cardiovascular mechanisms behind high output cardiac failure 
will improve our knowledge on hydrops fetalis, the final common pathway of 
many prenatal diseases.
6) To optimize fetal intrauterine transfusion policy, the use of additional intraperitoneal 
transfusion should be studied prospectively. Benefit of the combination of intravascular 
with intraperitoneal transfusion is the avoidance of a direct vascular overload during 
the transfusion, while obtaining the longest possible interval until delivery or subsequent 
transfusion. Possible downsides to this method could be prolonging of the intervention 
time, damage inflicted to the abdominal wall or the intestines, possibly causing fetal 
pain and intra-abdominal adhesions, or the induction of polycytemia. A new formula 
for the amount of donor blood that has to be given intravascularly and intraperitonally, 
has to be established for this prospective study. With the use of the studies in this 
thesis (chapters 6 and 7) this new formula can be established. A prospective study 
should be designed with the aim of safety analysis and with comprehensive pre- and 
postnatal neuro-imaging and (neurological) follow-up. 
A prospective study on the combination of intravascular and intraperitonal 





We want to advocate the importance of human fetal physiology research. In particular, 
the intrauterine transfusion is a unique situation where ultrasound measurements can 
be combined with blood sampling and other invasive diagnostics. Both the initial values 
as the reaction of the fetus on a therapeutic intervention makes it an ideal situation 
for physiological research. From the experience with alloimmunized hemolytic anemia 
and immune hydrops fetalis, we can translate our increased knowledge in fetal (patho-)
physiology to other prenatal diseases. Hereby, creating a basis for the development 
of new or improved fetal therapies for a wide range of prenatal diseases. 
Further, the similarities between (premature) neonates and fetuses of the same 
gestational age and the continuum of disease processes before and after birth, makes 
an intense cooperation between fetal medicine specialists and neonatologist, a goal 
that has to be strived for. Also, ongoing collaboration with specialized pediatricians 
e.g. in the field of cardiology, neurology and urology, and specialist e.g. in the field 
of radiology, pathology, embryology, hematology, immunology and genetics are 
essential for the development of fetal medicine. Joint ventures can increase the much 
needed chances to acces funding resources. Research at the beginning of life is 
poorly funded compared to research at the end of life [36]. The emphasis on the long 
term consequences should however obviate the importance of perinatal research.   
Fetal physiology research should continue to be performed, preferably in 
collaboration with other (pediatric) specialists and should emphasize the 
possibility that it will lead to the improvement of long term health 
consequences.   
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This thesis describes our research on fetal pathophysiology in hemolytic anemia 
and hydrops fetalis. Measurements performed in fetal blood as well as in amniotic 
fluid, before or during intrauterine red blood cell transfusion, where used for our 
studies. 
In chapter one, the motives leading to the studies presented in this thesis are 
described. As a tertiary fetal therapy centre, the LUMC provides a unique possibility 
to study fetal pathophysiology. Many prenatal potentially treatable diseases are 
accompanied by amniotic fluid volume abnormalities and the final stages are almost 
inevitably associated with hydrops fetalis. The final common pathway of these 
pathophysiological phenomenons is a shift in fluids and proteins between the different 
fetal compartments (intra- and extravascular). One specific question that arose from 
clinical practice was to understand the background of the diagnostic use of the 
bilirubin concentration in amniotic fluid to predict fetal anemia. Another question was, 
to understand the fetal reaction to severe anemia and intrauterine blood transfusions, 
and thus to improve the safety of this procedure. Background information is presented 
about fetal hemolytic anemia, the diagnosis of fetal anemia, intrauterine transfusion 
and hydrops fetalis.
In chapter two, in order to understand the Queenan or Liley chart, and thus the 
relation between fetal anemia and the rise in bilirubin concentration in amniotic fluid, 
we studied the relationship between the bilirubin concentration in amniotic fluid and 
in fetal blood. In 68 nonhydropic fetuses that received a first intrauterine blood 
transfusion, we compared amniotic fluid, taken shortly before transfusion, with the 
initial blood sample taken at the commencing of transfusion. All fetuses were anemic 
and had an increase in bilirubin concentration in their blood, although there was not 
a strong correlation between this concentration and the severity of the anemia. Most 
important finding was that the amniotic fluid/ fetal blood ratio of bilirubin in these 
affected cases was in accordance with the amniotic fluid/ fetal blood ratio of normal 
physiological bilirubin values. This amniotic fluid/ fetal blood ratio was dependent on 
gestational age. This can be explained by the fact that this ratio is determined by the 
binding of unconjugated bilirubin to albumin and thus by the amniotic fluid/ fetal blood 
ratio of albumin, during gestation. We hypothesized that of all the possible pathways, 
it is most plausible that bilirubin exchanges between fetal blood and amniotic fluid 
over the intramembraneous pathway. Exception to the normal amniotic fluid/ fetal 




In chapter three, we tested our hypothesis that the bilirubin concentration in amniotic 
fluid is determined by both the bilirubin concentration in fetal blood and the albumin 
concentration in fetal blood and in amniotic fluid. We measured bilirubin and albumin 
concentration in fetal blood and in amniotic fluid in 30 fetuses that received a first 
intrauterine blood transfusion. A strong correlation was found between the bilirubin 
to albumin ratio (BAR) in fetal blood and that in amniotic fluid, confirming our 
hypothesis. The BAR in fetal blood was consequently higher than the BAR in amniotic 
fluid though, possibly due to a difference in binding capacity of albumin in amniotic 
fluid compared to blood, for example due to a difference in pH. The slope in Queenan’s 
and Liley’s chart that has been used for years to predict the severity of fetal anemia, 
can now be understood: it can be explained by the corresponding slope of the albumin 
concentration in amniotic fluid during gestation. Exception to the consequent relation 
between the BAR in fetal blood and the BAR in amniotic fluid is described in 3 
severely hydropic fetuses.
In chapter four, we focused on the question what the origin of albumin is in the 
amniotic fluid. We reviewed the literature to assess the available evidence on the 
fetal, the maternal, and the placental or membrane origin of amniotic fluid albumin. 
Also, we speculated on the function of albumin in amniotic fluid. From the available 
evidence, we concluded that a fetal contribution is minimal in second and third 
trimester, mainly because of the low concentration of protein in fetal urine and lung 
fluid. A maternal contribution seems plausible, since other large proteins in amniotic 
fluid were already shown to be of maternal origin. Transfer can take place directly 
through the fetal membranes. Finally, the amniotic membrane itself also contributes 
to amniotic fluid albumin, although it is not known in what quantity. The concentration 
of amniotic fluid albumin may influence the volume of amniotic fluid through 
maintenance of osmotic pressure or through regulation of receptors involved in 
amniotic fluid amount and composition. Albumin could have an important role as a 
carrier protein, for example for fatty acids. Considering its non-fetal origin it could 
also be an important addition to prenatal transplacental nutrition. Different suggestions 
are proposed to investigate the origin, the transport mechanisms, and the function 
of albumin in amniotic fluid.
In chapter five, we studied the role of a low albumin concentration in fetal blood on 
the development of hydrops fetalis. Data was collected from 224 fetuses that received 
a first intrauterine blood transfusion due to Rh-D alloimmunization. We included 161 
nonhydropic, 44 mildly hydropic and 19 severely hydropic fetuses. Relative hemoglobin 




at commencing of the procedure. A decrease in albumin concentration occurred only 
at a hemoglobin deficit below 8 standard deviations below the normal mean. Although 
the percentage of fetuses with a low albumin concentration was highest in severely 
hydropic fetuses (63%), it was much less in mildly hydropic fetuses (14%) and also 
occasionally present in nonhydropic fetuses (6%). Overall 73% of the hydropic fetuses 
had a normal albumin concentration. It therefore was concluded that a low albumin 
concentration in fetal blood is most likely a secondary effect and not the initial cause 
of hydrops in fetal anemia. In our study, both a low concentration of albumin and 
presence of severe anemia were independently predictive for the presence of 
hydrops. 
In chapter six, the relationship between severity of anemia or presence of hydrops 
and the fetoplacental blood volume was assessed. We calculated fetal total blood 
volume in 86 fetuses that received a first intrauterine blood transfusion. The blood 
volume was calculated on the basis of a dilutional principle, namely of the fetal 
hemoglobin that was present at the beginning of the transfusion with the adult (donor) 
hemoglobin. The average fetal total blood volume was 123 ml/kg in nonhydropic 
fetuses and 144 ml/kg in hydropic fetuses. There was no relation between severity 
of anemia and blood volume, corrected for fetal weight. This implies that fetuses 
maintain their blood volume even in severe anemia and compensate for the loss of 
red cells with an equal increase in plasma volume. In hydropic fetuses, there even 
seems to take place an overcompensation of plasma volume. This is in accordance 
with the hypothesis that congestive heart failure plays a role in the pathophysiology 
of hydrops in anemic fetuses.
In chapter seven, we aimed to study the fluid shift that takes place out of the fetal 
circulation during an intrauterine blood transfusion. The effect of volume and speed 
of transfusion, and the severity of anemia and presence of hydrops were analyzed. 
In 95 fetuses, we calculated fluid shift at first intrauterine transfusions, by determining 
initial and final blood volumes. We found that on average 36% of the transfused 
volume already leaves the circulation during transfusion. Volume of fluid shift was 
related to the volume of donor blood that was administered. The fluid shift was 
however inversely related to the speed of transfusion, implying that this shift takes 
time, making it probable that this process continues in the hours after the transfusion. 
Severity of anemia and presence of hydrops surprisingly had no evident effect on 
the amount of fluid shift, possibly because they can have different contradictory 
effects on the cardiovascular system. Further, we found that at low gestational age, 




transfusion. Transfusion policy should therefore be adjusted to gestational age. It 
should also be considered that the hematocrit still increases after transfusion, 
potentially leading to unintentional high hematocrit values and hyperviscosity of the 
fetal blood during the days following transfusion. 
In chapter eight, the new insights acquired in this thesis are summarized. Among 
others, the differences between the fluid and protein dynamics in fetuses and in 
neonates are discussed. Our findings led to several implications for current practice. 
Finally, proposals for future research are described.   
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Dit proefschrift beschrijft onderzoek naar hemolytische foetale bloedarmoede en 
foetale hydrops. Hemolytische foetale bloedarmoede ontstaat door afbraak van rode 
bloedcellen. Foetale hydrops betreft het vasthouden van te veel vocht in het lichaam, 
die door chronische  bloedarmoede kan ontstaan. Metingen in het kader van onze 
studies werden zowel in foetaal bloed als in vruchtwater verricht, vlak voor of tijdens 
intrauteriene bloedtransfusies (bloedtransfusies die, via een lange naald, gegeven 
worden aan kinderen in de baarmoeder). 
In hoofdstuk één worden de achtergronden weergegeven die hebben geleid tot de 
onderzoeken, beschreven in dit proefschrift. Aangezien het LUMC een tertiair 
verwijscentrum voor foetale therapie is, bestaat hier een unieke mogelijkheid om 
ziektes van de ongeborene te bestuderen. Potentieel behandelbare prenatale ziektes 
gaan vaak gepaard met abnormale hoeveelheid vruchtwater. Over het algemeen is 
het eindstadium van deze ziektes foetale hydrops. Zowel bij abnormale vruchtwater 
hoeveelheden als bij hydrops is er sprake van een verschuiving in vocht en eiwitten 
tussen verschillende foetale compartimenten (binnen en buiten de bloedbaan). Een 
van de ziektes waarbij hydrops op kan treden is foetale bloedarmoede. Sinds enige 
decennia is bepaling van bilirubine (een afbraakproduct van hemoglobine in rode 
bloedcellen) in het vruchtwater de methode om bloedarmoede bij de foetus te 
voorspellen. Een vraag vanuit de kliniek was hoe deze relatie bepaald wordt. Een 
andere onderzoeksvraag was, hoe de foetus reageert op ernstige bloedarmoede en 
op intrauteriene bloedtransfusies, met het doel de veiligheid van deze behandeling 
te kunnen verbeteren. Tenslotte wordt achtergrondinformatie gegeven over foetale 
bloedarmoede door afbraak van rode bloedcellen, over de mogelijkheden van 
diagnostiek naar foetale bloedarmoede, over intrauteriene bloedtransfusie en over 
foetale hydrops. 
In hoofdstuk twee wordt de relatie tussen de bilirubine concentratie in vruchtwater 
en die in foetaal bloed bestudeerd, met als doel de Queenan of Liley testen (die een 
relatie leggen tussen foetale bloedarmoede en de stijging van bilirubine in vruchtwater) 
te begrijpen. In 68 niet hydropische foetussen, die hun eerste intrauteriene 
bloedtransfusie ontvingen, werd het vruchtwater, afgenomen vlak voor de transfusie, 
vergeleken met het initiële bloedmonster, afgenomen bij aanvang van de transfusie. 
Alhoewel alle foetussen bloedarmoede en een verhoogd bilirubine gehalte in het 
bloed hadden, was er geen sterke relatie tussen de mate van bloedarmoede en de 
hoogte van de bilirubine concentratie. Belangrijkste bevinding was dat de verhouding 
van het bilirubine gehalte in vruchtwater ten opzichte van bloed in deze aangedane 




van foetaal bloed in niet aangedane zwangerschappen (referentiewaardes uit de 
literatuur). Deze vruchtwater/ bloed verhouding was afhankelijk van de 
zwangerschapsduur. Dit kan verklaard worden door het feit dat deze verhouding 
bepaald wordt door de binding van bilirubine aan albumine (een bindingseiwit) en dus 
door de verhouding van het albumine gehalte in vruchtwater ten opzicht van bloed, 
gedurende de zwangerschap. We formuleerden de hypothese dat van alle mogelijke 
transportwegen het meest waarschijnlijk is dat bilirubine uitwisselt tussen foetaal 
bloed en vruchtwater door de vliezen die het vruchtwater omringen (met name het 
oppervlakte van de placenta waar vruchtwater en veel foetale bloedvaten zich vlak 
naast elkaar bevinden). We beschrijven een uitzondering van de normale verhouding 
van bilirubine in vruchtwater ten opzichte van bloed in 6 foetussen die ernstig 
hydropisch waren.
In hoofdstuk drie testten we onze hypothese dat de bilirubine concentratie in 
vruchtwater bepaald wordt door zowel de bilirubine concentratie in het foetale bloed 
als de albumine concentraties in foetaal bloed en in vruchtwater. We maten de 
bilirubine en albumine concentratie in foetaal bloed en in vruchtwater in 30 foetussen 
die een eerste bloedtransfusie kregen. Er werd een sterke relatie gevonden tussen 
de bilirubine tot albumine ratio (BAR) in het foetale bloed en die in vruchtwater, wat 
onze hypothese bevestigde. De BAR in het foetale bloed was echter altijd hoger dan 
de BAR in vruchtwater, mogelijk door een verschil in bindingscapaciteit van albumine 
in vruchtwater ten opzicht van bloed, bijvoorbeeld als gevolg van het verschil in pH 
tussen bloed en vruchtwater. De curve in de grafiek van de Queenan of Liley test 
kan nu goed begrepen worden: deze wordt verklaard door het verloop van de normale 
albumine concentratie in vruchtwater gedurende de zwangerschap. We beschrijven 
een uitzondering op de constante relatie van de BAR in bloed ten opzichte van de 
BAR in vruchtwater bij 3 foetussen die ernstig hydropisch waren.
In hoofdstuk vier richtten we ons op de vraag hoe albumine in het vruchtwater 
terecht komt. We zochten in de literatuur naar bewijsmateriaal voor een foetale 
oorsprong, een moederlijke oorsprong of een oorsprong in de placenta of de vliezen, 
van het albumine dat in vruchtwater aanwezig is. We zochten ook naar aanwijzingen 
voor de mogelijke functie van albumine in vruchtwater. Uit de beschikbare gegevens 
concludeerden we dat een foetale bijdrage heel klein is in het tweede en derde 
trimester van de zwangerschap, voornamelijk omdat de concentratie van eiwit heel 
laag is in foetale urine en longvocht. Een moederlijke oorsprong van albumine in 
vruchtwater lijkt wel waarschijnlijk aangezien van andere grote eiwitten in vruchtwater 
reeds is aangetoond dat deze van moederlijke oorsprong zijn. Transport kan 
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rechtstreeks door de foetale vliezen plaats vinden. Tenslotte levert het amnionvlies 
zelf een bijdrage aan albumine in vruchtwater, hoewel het onbekend is in welke 
hoeveelheid. De concentratie van albumine in vruchtwater zou het volume van het 
vruchtwater kunnen beïnvloeden door het behouden van osmotische druk of door 
regulatie van receptoren die betrokken zijn bij het bepalen van de vruchtwater 
hoeveelheid en samenstelling. Albumine zou een belangrijke rol kunnen hebben als 
transporteiwit, bijvoorbeeld voor vetzuren. Rekening houdend met de mogelijk niet 
foetale oorsprong van albumine zou het ook een belangrijke aanvulling kunnen zijn 
op prenatale, via de placenta verkregen, voeding. Verschillende suggesties worden 
gedaan om de oorsprong, de transportmechanismen en de functie van albumine in 
vruchtwater verder te onderzoeken.
In hoofdstuk vijf beschrijven we de rol die een lage albumine concentratie in het 
bloed zou kunnen hebben op de ontwikkeling van foetale hydrops. Gegevens  van 
224 foetussen die een eerste bloedtransfusie kregen in verband met Rhesus-D 
immunisatie, werden verzameld. Het betrof 161 niet hydropische, 44 mild hydropische 
en 19 ernstig hydropische foetussen. Het relatieve hemoglobine en albumine tekort, 
beide gecorrigeerd voor zwangerschapsduur, werden bepaald voor aanvang van de 
transfusie. Een verlaging van de albumine concentratie kwam alleen voor bij een 
hemoglobine tekort van meer dan 8 standaard deviaties onder het normale 
gemiddelde. Hoewel het percentage van een te laag albumine gehalte het hoogste 
was bij ernstig hydropische foetussen (63%), was dit veel minder bij mild hydropische 
foetussen (14%) doch ook incidenteel verlaagd bij niet hydropische foetussen (6%). 
Al met al hadden 73% van de hydropische foetussen een normaal albumine gehalte. 
We concludeerden daarom dat een te laag albumine meest waarschijnlijk een 
secundair effect is en niet de oorspronkelijke oorzaak van hydrops bij foetale 
bloedarmoede. Uit ons onderzoek bleek dat een laag albumine gehalte en een laag 
hemoglobine gehalte onafhankelijke voorspellers waren voor de aanwezigheid van 
hydrops. 
 
In hoofdstuk zes onderzochten we de relatie tussen de ernst van de bloedarmoede 
en de aanwezigheid van hydrops met het foetoplacentaire bloedvolume (het bloed 
dat circuleert door de foetus, de navelstreng en de placenta). We berekenden het 
bloedvolume in 86 foetussen die een eerste bloedtransfusie ontvingen. Het 
bloedvolume werd berekend op basis van een verdunningsprincipe, van het reeds 
aanwezige foetaal hemoglobine met volwassen (donor) hemoglobine. Het gemiddelde 
foetale bloedvolume was 123 ml/kg in niet hydropische foetussen en 144 ml/kg in 




en het bloedvolume dat gecorrigeerd was voor foetaal gewicht. Dit impliceert dat 
foetussen hun bloedvolume constant kunnen houden, zelfs in geval van ernstige 
bloedarmoede, en het verlies van rode bloedcellen dus compenseren met een gelijke 
hoeveelheid plasma volume. In hydropische foetussen lijkt er zelfs een 
overcompensatie te zijn van het plasma volume. Dit past bij de hypothese dat hartfalen 
een rol speelt bij het ontstaan van hydrops bij foetussen met bloedarmoede.
In hoofdstuk zeven hebben we de vochtverplaatsing uit de foetale bloedbaan 
bestudeerd die plaats vindt tijdens een intrauteriene bloedtransfusie. Het effect van 
het volume van transfusie, de snelheid van transfusie, de ernst van bloedarmoede 
en de aanwezigheid van hydrops werden geanalyseerd. In 95 foetussen berekenden 
we de vochtverplaatsing tijdens een eerste intrauteriene bloedtransfusie, door het 
oorspronkelijke bloedvolume en het bloedvolume op het einde van de transfusie te 
bepalen. We vonden dat gemiddeld 36% van het volume dat gegeven werd tijdens 
de transfusie de foetale bloedbaan direct verlaat. De hoeveelheid vochtverplaatsing 
was gerelateerd aan de hoeveelheid transfusiebloed die werd gegeven. De 
hoeveelheid vochtverplaatsing was echter omgekeerd evenredig aan de snelheid van 
transfusie, implicerend dat dit proces tijd vergt, wat het waarschijnlijk maakt dat het 
proces van vochtverplaatsing nog verder gaat in de uren na de transfusie. De ernst 
van de bloedarmoede en de aanwezigheid van hydrops hadden verrassend genoeg 
geen evident effect op de hoeveelheid vochtverplaatsing, mogelijk omdat verschillende 
tegengestelde effecten op het cardiovasculaire systeem plaats kunnen vinden in 
deze situaties. Verder vonden we dat bij een lage zwangerschapsduur de foetussen 
met een relatief hoog volume en een hoge snelheid van transfusie werden belast. 
Het transfusie beleid zou dan ook aangepast moeten worden aan de hand van de 
zwangerschapsduur. Bovendien zou rekening gehouden moeten worden met de 
mogelijkheid dat het hematocriet (het bloedgehalte) nog doorstijgt na afloop van de 
transfusie, met als mogelijk gevolg een onbedoeld hoog hematocriet en hyperviscositeit 
van het foetale bloed in de dagen na de transfusie.
In hoofdstuk acht worden de nieuwe inzichten die verkregen zijn in dit proefschrift, 
samengevat. Onder meer het verschil tussen de vocht- en eiwithuishouding bij 
foetussen en bij pasgeborenen wordt beschreven. Vervolgens worden verschillende 
implicaties voor de huidige praktijk beschreven. Tenslotte worden verschillende 






LUMC  =  Leiden University Medical Center
IgG  =  Immunoglobulin G
Rh D  =  Rhesus D (antibody)
Delta OD450  =   Delta Optical Density 450 
(spectrophotometric measurement)
CMV  = Cytomegalovirus
IUT  = Intrauterine transfusion
ADCC  =  Antibody-Dependent Cell-mediated Cytotoxicity assay
BAR  =  Bilirubin/ albumin ratio
FPV  =  Feto-placental blood volume
RCV  =  Red cell volume
Hb  =  Hemoglobin
Ht  =  Hematocrit
MCHC   =  Mean Corpuscular Hemoglobin Concentration
Alb  =  Albumin
AFP  =  Alpha-feto protein
SD  =  Standard deviation
SE  =  Standard error
95%CI   =  95% Confidence interval 
ROC curve  =  Receiver operating characteristics curve
p  =  probability
R2  =  Coefficient of determination
L  =  liter
dL  =  deciliter
ml  =  milliliter
kg  =  kilogram
g  =  gram
mg  =  milligram
mmol  =  millimol
nm  =  nanometer
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